WO2007048866A1 - PROCEDIMIENTO Y DISPOSITIVO DE ANÁLISIS IN VITRO DE mRNA DE GENES IMPLICADOS EN NEOPLASIAS HEMATOLÓGICAS - Google Patents
PROCEDIMIENTO Y DISPOSITIVO DE ANÁLISIS IN VITRO DE mRNA DE GENES IMPLICADOS EN NEOPLASIAS HEMATOLÓGICAS Download PDFInfo
- Publication number
- WO2007048866A1 WO2007048866A1 PCT/ES2006/070054 ES2006070054W WO2007048866A1 WO 2007048866 A1 WO2007048866 A1 WO 2007048866A1 ES 2006070054 W ES2006070054 W ES 2006070054W WO 2007048866 A1 WO2007048866 A1 WO 2007048866A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sgl
- oligonucleotides
- vitro
- samples
- genes
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 195
- 238000000034 method Methods 0.000 title claims abstract description 120
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 94
- 238000000338 in vitro Methods 0.000 title claims abstract description 65
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 33
- 230000009826 neoplastic cell growth Effects 0.000 title claims abstract description 9
- 238000004458 analytical method Methods 0.000 title abstract description 25
- 230000002489 hematologic effect Effects 0.000 title abstract description 6
- 239000000523 sample Substances 0.000 claims abstract description 129
- 230000014509 gene expression Effects 0.000 claims abstract description 107
- 238000002493 microarray Methods 0.000 claims abstract description 81
- 238000009396 hybridization Methods 0.000 claims abstract description 58
- 238000003745 diagnosis Methods 0.000 claims abstract description 43
- 230000008569 process Effects 0.000 claims abstract description 24
- 238000004393 prognosis Methods 0.000 claims abstract description 24
- 239000012472 biological sample Substances 0.000 claims abstract description 11
- 108091034117 Oligonucleotide Proteins 0.000 claims description 193
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 143
- -1 ABCBl Proteins 0.000 claims description 129
- 210000004027 cell Anatomy 0.000 claims description 89
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 48
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 46
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 45
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 36
- 208000032839 leukemia Diseases 0.000 claims description 31
- 210000004369 blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 25
- 230000000295 complement effect Effects 0.000 claims description 21
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 20
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 19
- 230000000750 progressive effect Effects 0.000 claims description 19
- 238000010606 normalization Methods 0.000 claims description 18
- 238000007619 statistical method Methods 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 16
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 claims description 14
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims description 14
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 14
- 239000011521 glass Substances 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 14
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims description 13
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims description 13
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 13
- 238000011156 evaluation Methods 0.000 claims description 13
- 108091059597 FAIM3 Proteins 0.000 claims description 12
- 102100037815 Fas apoptotic inhibitory molecule 3 Human genes 0.000 claims description 12
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 claims description 12
- 101000592466 Homo sapiens Proteasome subunit beta type-4 Proteins 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 11
- 102100033417 Glucocorticoid receptor Human genes 0.000 claims description 11
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 11
- 101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 claims description 11
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 claims description 11
- 101001000773 Homo sapiens POU domain, class 2, transcription factor 2 Proteins 0.000 claims description 11
- 102100033190 Proteasome subunit beta type-4 Human genes 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 102100028186 ATP-binding cassette sub-family C member 5 Human genes 0.000 claims description 10
- 102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 claims description 10
- 101000986622 Homo sapiens ATP-binding cassette sub-family C member 5 Proteins 0.000 claims description 10
- 101150093282 SG12 gene Proteins 0.000 claims description 10
- 108010005713 bis(5'-adenosyl)triphosphatase Proteins 0.000 claims description 10
- 230000003394 haemopoietic effect Effects 0.000 claims description 10
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 claims description 9
- 102100027829 DNA repair protein XRCC3 Human genes 0.000 claims description 9
- 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 claims description 9
- 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 claims description 9
- 101001109282 Homo sapiens NudC domain-containing protein 1 Proteins 0.000 claims description 9
- 101000665882 Homo sapiens Retinol-binding protein 4 Proteins 0.000 claims description 9
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 9
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 9
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 9
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 claims description 9
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 claims description 9
- 102100022475 NudC domain-containing protein 1 Human genes 0.000 claims description 9
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 claims description 9
- 102100038246 Retinol-binding protein 4 Human genes 0.000 claims description 9
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 9
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 9
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 9
- 108010074310 X-ray repair cross complementing protein 3 Proteins 0.000 claims description 9
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 claims description 9
- 239000013641 positive control Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 claims description 8
- 238000007477 logistic regression Methods 0.000 claims description 8
- 210000005259 peripheral blood Anatomy 0.000 claims description 8
- 239000011886 peripheral blood Substances 0.000 claims description 8
- 208000027409 severe congenital neutropenia 7 Diseases 0.000 claims description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 7
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 7
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 claims description 7
- 239000013642 negative control Substances 0.000 claims description 7
- 208000027390 severe congenital neutropenia 3 Diseases 0.000 claims description 7
- 208000027391 severe congenital neutropenia 6 Diseases 0.000 claims description 7
- 208000027396 severe congenital neutropenia 8 Diseases 0.000 claims description 7
- 102100034858 Homeobox protein Hox-D8 Human genes 0.000 claims description 6
- 101001019776 Homo sapiens Homeobox protein Hox-D8 Proteins 0.000 claims description 6
- 208000027392 severe congenital neutropenia 2 Diseases 0.000 claims description 6
- 230000006641 stabilisation Effects 0.000 claims description 6
- 238000011105 stabilization Methods 0.000 claims description 6
- 102100038918 Caspase-6 Human genes 0.000 claims description 5
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 claims description 5
- 108020004463 18S ribosomal RNA Proteins 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 102100037991 85/88 kDa calcium-independent phospholipase A2 Human genes 0.000 claims description 3
- 108050006400 Cyclin Proteins 0.000 claims description 3
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 claims description 3
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 claims description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 3
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 3
- 101000573199 Homo sapiens Protein PML Proteins 0.000 claims description 3
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims description 3
- 102000026633 IL6 Human genes 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 101710125553 PLA2G6 Proteins 0.000 claims description 3
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims description 3
- 102100026375 Protein PML Human genes 0.000 claims description 3
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims description 3
- 108010090804 Streptavidin Proteins 0.000 claims description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 3
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 3
- 230000008488 polyadenylation Effects 0.000 claims description 3
- 238000010186 staining Methods 0.000 claims description 3
- FDFPSNISSMYYDS-UHFFFAOYSA-N 2-ethyl-N,2-dimethylheptanamide Chemical compound CCCCCC(C)(CC)C(=O)NC FDFPSNISSMYYDS-UHFFFAOYSA-N 0.000 claims description 2
- 102100036657 26S proteasome non-ATPase regulatory subunit 7 Human genes 0.000 claims description 2
- 102100036563 26S proteasome regulatory subunit 8 Human genes 0.000 claims description 2
- 102100027561 39S ribosomal protein L37, mitochondrial Human genes 0.000 claims description 2
- SXXLKZCNJHJYFL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[4,5-c]pyridin-5-ium-3-olate Chemical compound C1CNCC2=C1ONC2=O SXXLKZCNJHJYFL-UHFFFAOYSA-N 0.000 claims description 2
- 102100033409 40S ribosomal protein S3 Human genes 0.000 claims description 2
- 102100023779 40S ribosomal protein S5 Human genes 0.000 claims description 2
- 102100033731 40S ribosomal protein S9 Human genes 0.000 claims description 2
- 102100035322 60S ribosomal protein L24 Human genes 0.000 claims description 2
- 102100031002 60S ribosomal protein L36a Human genes 0.000 claims description 2
- 102100036126 60S ribosomal protein L37a Human genes 0.000 claims description 2
- 102100040623 60S ribosomal protein L41 Human genes 0.000 claims description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 2
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 claims description 2
- 102100040193 ADP-ribosylation factor-binding protein GGA3 Human genes 0.000 claims description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 2
- 102000000872 ATM Human genes 0.000 claims description 2
- 102100021870 ATP synthase subunit O, mitochondrial Human genes 0.000 claims description 2
- 102100028162 ATP-binding cassette sub-family C member 3 Human genes 0.000 claims description 2
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 claims description 2
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 2
- 102100036818 Ankyrin-2 Human genes 0.000 claims description 2
- 102100034278 Annexin A6 Human genes 0.000 claims description 2
- 102100034273 Annexin A7 Human genes 0.000 claims description 2
- 102100027308 Apoptosis regulator BAX Human genes 0.000 claims description 2
- 108050006685 Apoptosis regulator BAX Proteins 0.000 claims description 2
- 102100023927 Asparagine synthetase [glutamine-hydrolyzing] Human genes 0.000 claims description 2
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 2
- 102100020823 Autophagy-related protein 9A Human genes 0.000 claims description 2
- 108700009171 B-Cell Lymphoma 3 Proteins 0.000 claims description 2
- 102100021630 B-cell CLL/lymphoma 7 protein family member A Human genes 0.000 claims description 2
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 2
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 108091012583 BCL2 Proteins 0.000 claims description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 2
- 102100023973 Bax inhibitor 1 Human genes 0.000 claims description 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 2
- 102100021334 Bcl-2-related protein A1 Human genes 0.000 claims description 2
- 101150008012 Bcl2l1 gene Proteins 0.000 claims description 2
- 101150072667 Bcl3 gene Proteins 0.000 claims description 2
- 102100027058 Bleomycin hydrolase Human genes 0.000 claims description 2
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 2
- 102100031746 Bone sialoprotein 2 Human genes 0.000 claims description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims description 2
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 claims description 2
- 102100034799 CCAAT/enhancer-binding protein delta Human genes 0.000 claims description 2
- 108010017009 CD11b Antigen Proteins 0.000 claims description 2
- 108010049990 CD13 Antigens Proteins 0.000 claims description 2
- 102000049320 CD36 Human genes 0.000 claims description 2
- 108010045374 CD36 Antigens Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 2
- 102100027221 CD81 antigen Human genes 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 102100037904 CD9 antigen Human genes 0.000 claims description 2
- 102100027098 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Human genes 0.000 claims description 2
- 102100036361 Calcium-binding and coiled-coil domain-containing protein 2 Human genes 0.000 claims description 2
- 102100033040 Carbonic anhydrase 12 Human genes 0.000 claims description 2
- 108090000397 Caspase 3 Proteins 0.000 claims description 2
- 102100029855 Caspase-3 Human genes 0.000 claims description 2
- 102100025597 Caspase-4 Human genes 0.000 claims description 2
- 102100038916 Caspase-5 Human genes 0.000 claims description 2
- 108010060313 Core Binding Factor beta Subunit Proteins 0.000 claims description 2
- 102000008147 Core Binding Factor beta Subunit Human genes 0.000 claims description 2
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 claims description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 2
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 claims description 2
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 claims description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims description 2
- 108010009367 Cyclin-Dependent Kinase Inhibitor p18 Proteins 0.000 claims description 2
- 102000009503 Cyclin-Dependent Kinase Inhibitor p18 Human genes 0.000 claims description 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 2
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 claims description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 2
- 102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 claims description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims description 2
- 102100032522 Cyclin-dependent kinases regulatory subunit 2 Human genes 0.000 claims description 2
- 102100026846 Cytidine deaminase Human genes 0.000 claims description 2
- 108010031325 Cytidine deaminase Proteins 0.000 claims description 2
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 claims description 2
- 102100039524 DNA endonuclease RBBP8 Human genes 0.000 claims description 2
- 102100031866 DNA excision repair protein ERCC-5 Human genes 0.000 claims description 2
- 108010035476 DNA excision repair protein ERCC-5 Proteins 0.000 claims description 2
- 102100031867 DNA excision repair protein ERCC-6 Human genes 0.000 claims description 2
- 102100039606 DNA replication licensing factor MCM3 Human genes 0.000 claims description 2
- 102100033711 DNA replication licensing factor MCM7 Human genes 0.000 claims description 2
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 claims description 2
- 102100027642 DNA-binding protein inhibitor ID-2 Human genes 0.000 claims description 2
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 claims description 2
- 102100029588 Deoxycytidine kinase Human genes 0.000 claims description 2
- 102100022878 Deoxyribonuclease-2-beta Human genes 0.000 claims description 2
- 101100226017 Dictyostelium discoideum repD gene Proteins 0.000 claims description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 2
- 102100025189 E3 ubiquitin-protein ligase RBBP6 Human genes 0.000 claims description 2
- 102100037460 E3 ubiquitin-protein ligase Topors Human genes 0.000 claims description 2
- 101150105460 ERCC2 gene Proteins 0.000 claims description 2
- 102100040465 Elongation factor 1-beta Human genes 0.000 claims description 2
- 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 claims description 2
- 102100029782 Eukaryotic translation initiation factor 3 subunit I Human genes 0.000 claims description 2
- 102100029602 Eukaryotic translation initiation factor 4B Human genes 0.000 claims description 2
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 claims description 2
- 102100032837 Exportin-6 Human genes 0.000 claims description 2
- 102100026693 FAS-associated death domain protein Human genes 0.000 claims description 2
- 102100030421 Fatty acid-binding protein 5 Human genes 0.000 claims description 2
- 102100027944 Flavin reductase (NADPH) Human genes 0.000 claims description 2
- 102100021245 G-protein coupled receptor 183 Human genes 0.000 claims description 2
- 101710101406 G-protein coupled receptor 183 Proteins 0.000 claims description 2
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 claims description 2
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 claims description 2
- 102100035205 GA-binding protein subunit beta-1 Human genes 0.000 claims description 2
- 108010001517 Galectin 3 Proteins 0.000 claims description 2
- 102000000802 Galectin 3 Human genes 0.000 claims description 2
- 102100039555 Galectin-7 Human genes 0.000 claims description 2
- 102100035695 Gamma-aminobutyric acid receptor-associated protein Human genes 0.000 claims description 2
- 102100031885 General transcription and DNA repair factor IIH helicase subunit XPB Human genes 0.000 claims description 2
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 claims description 2
- 102100030479 Germinal center-associated signaling and motility protein Human genes 0.000 claims description 2
- 102100030669 Glutamate receptor 3 Human genes 0.000 claims description 2
- 102100020972 Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Human genes 0.000 claims description 2
- 102100040094 Glycogen phosphorylase, brain form Human genes 0.000 claims description 2
- 102100021185 Guanine nucleotide-binding protein-like 3 Human genes 0.000 claims description 2
- 108091059596 H3F3A Proteins 0.000 claims description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 2
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 102100024001 Hepatic leukemia factor Human genes 0.000 claims description 2
- 102100033997 Heterogeneous nuclear ribonucleoprotein H3 Human genes 0.000 claims description 2
- 102100028818 Heterogeneous nuclear ribonucleoprotein L Human genes 0.000 claims description 2
- 102100034533 Histone H2AX Human genes 0.000 claims description 2
- 102100021638 Histone H2B type 1-N Human genes 0.000 claims description 2
- 102100039236 Histone H3.3 Human genes 0.000 claims description 2
- 102100025190 Histone-binding protein RBBP4 Human genes 0.000 claims description 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 2
- 101001136696 Homo sapiens 26S proteasome non-ATPase regulatory subunit 7 Proteins 0.000 claims description 2
- 101001136753 Homo sapiens 26S proteasome regulatory subunit 8 Proteins 0.000 claims description 2
- 101000650303 Homo sapiens 39S ribosomal protein L37, mitochondrial Proteins 0.000 claims description 2
- 101000656561 Homo sapiens 40S ribosomal protein S3 Proteins 0.000 claims description 2
- 101000622644 Homo sapiens 40S ribosomal protein S5 Proteins 0.000 claims description 2
- 101000657066 Homo sapiens 40S ribosomal protein S9 Proteins 0.000 claims description 2
- 101000660926 Homo sapiens 60S ribosomal protein L24 Proteins 0.000 claims description 2
- 101001127203 Homo sapiens 60S ribosomal protein L36a Proteins 0.000 claims description 2
- 101001127258 Homo sapiens 60S ribosomal protein L36a-like Proteins 0.000 claims description 2
- 101001092424 Homo sapiens 60S ribosomal protein L37a Proteins 0.000 claims description 2
- 101000674326 Homo sapiens 60S ribosomal protein L41 Proteins 0.000 claims description 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 2
- 101001037079 Homo sapiens ADP-ribosylation factor-binding protein GGA3 Proteins 0.000 claims description 2
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims description 2
- 101000970995 Homo sapiens ATP synthase subunit O, mitochondrial Proteins 0.000 claims description 2
- 101000986633 Homo sapiens ATP-binding cassette sub-family C member 3 Proteins 0.000 claims description 2
- 101000986621 Homo sapiens ATP-binding cassette sub-family C member 6 Proteins 0.000 claims description 2
- 101000928344 Homo sapiens Ankyrin-2 Proteins 0.000 claims description 2
- 101000780137 Homo sapiens Annexin A6 Proteins 0.000 claims description 2
- 101000780144 Homo sapiens Annexin A7 Proteins 0.000 claims description 2
- 101000975992 Homo sapiens Asparagine synthetase [glutamine-hydrolyzing] Proteins 0.000 claims description 2
- 101000785057 Homo sapiens Autophagy-related protein 9A Proteins 0.000 claims description 2
- 101000971230 Homo sapiens B-cell CLL/lymphoma 7 protein family member A Proteins 0.000 claims description 2
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 2
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000903937 Homo sapiens Bax inhibitor 1 Proteins 0.000 claims description 2
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 claims description 2
- 101000984541 Homo sapiens Bleomycin hydrolase Proteins 0.000 claims description 2
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 claims description 2
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 2
- 101000707248 Homo sapiens Bone sialoprotein 2 Proteins 0.000 claims description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 2
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 2
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 claims description 2
- 101000945965 Homo sapiens CCAAT/enhancer-binding protein delta Proteins 0.000 claims description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 2
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 2
- 101000836774 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Proteins 0.000 claims description 2
- 101000714579 Homo sapiens Calcium-binding and coiled-coil domain-containing protein 2 Proteins 0.000 claims description 2
- 101000867855 Homo sapiens Carbonic anhydrase 12 Proteins 0.000 claims description 2
- 101000933112 Homo sapiens Caspase-4 Proteins 0.000 claims description 2
- 101000741072 Homo sapiens Caspase-5 Proteins 0.000 claims description 2
- 101000851684 Homo sapiens Chimeric ERCC6-PGBD3 protein Proteins 0.000 claims description 2
- 101000858031 Homo sapiens Coxsackievirus and adenovirus receptor Proteins 0.000 claims description 2
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims description 2
- 101000942317 Homo sapiens Cyclin-dependent kinases regulatory subunit 2 Proteins 0.000 claims description 2
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 claims description 2
- 101000746134 Homo sapiens DNA endonuclease RBBP8 Proteins 0.000 claims description 2
- 101000920783 Homo sapiens DNA excision repair protein ERCC-6 Proteins 0.000 claims description 2
- 101000963174 Homo sapiens DNA replication licensing factor MCM3 Proteins 0.000 claims description 2
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 claims description 2
- 101001081582 Homo sapiens DNA-binding protein inhibitor ID-2 Proteins 0.000 claims description 2
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 claims description 2
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims description 2
- 101001077300 Homo sapiens E3 ubiquitin-protein ligase RBBP6 Proteins 0.000 claims description 2
- 101000662670 Homo sapiens E3 ubiquitin-protein ligase Topors Proteins 0.000 claims description 2
- 101000967447 Homo sapiens Elongation factor 1-beta Proteins 0.000 claims description 2
- 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 claims description 2
- 101001012704 Homo sapiens Eukaryotic translation initiation factor 3 subunit I Proteins 0.000 claims description 2
- 101000840282 Homo sapiens Eukaryotic translation initiation factor 4B Proteins 0.000 claims description 2
- 101001054354 Homo sapiens Eukaryotic translation initiation factor 5A-1 Proteins 0.000 claims description 2
- 101000847050 Homo sapiens Exportin-6 Proteins 0.000 claims description 2
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 claims description 2
- 101001062855 Homo sapiens Fatty acid-binding protein 5 Proteins 0.000 claims description 2
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 claims description 2
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 claims description 2
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 claims description 2
- 101001022098 Homo sapiens GA-binding protein subunit beta-1 Proteins 0.000 claims description 2
- 101001022101 Homo sapiens GA-binding protein subunit beta-2 Proteins 0.000 claims description 2
- 101000608772 Homo sapiens Galectin-7 Proteins 0.000 claims description 2
- 101001001372 Homo sapiens Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 claims description 2
- 101000920748 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPB Proteins 0.000 claims description 2
- 101000862655 Homo sapiens Germinal center-associated signaling and motility protein Proteins 0.000 claims description 2
- 101001010434 Homo sapiens Glutamate receptor 3 Proteins 0.000 claims description 2
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 claims description 2
- 101000748183 Homo sapiens Glycogen phosphorylase, brain form Proteins 0.000 claims description 2
- 101001040748 Homo sapiens Guanine nucleotide-binding protein-like 3 Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101001017561 Homo sapiens Heterogeneous nuclear ribonucleoprotein H3 Proteins 0.000 claims description 2
- 101000839078 Homo sapiens Heterogeneous nuclear ribonucleoprotein L Proteins 0.000 claims description 2
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 claims description 2
- 101000898897 Homo sapiens Histone H2B type 1-N Proteins 0.000 claims description 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 2
- 101001081176 Homo sapiens Hyaluronan mediated motility receptor Proteins 0.000 claims description 2
- 101000978133 Homo sapiens Immunoglobulin lambda variable 6-57 Proteins 0.000 claims description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 2
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims description 2
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 claims description 2
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 claims description 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 2
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 claims description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 2
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims description 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 101001011393 Homo sapiens Interferon regulatory factor 2 Proteins 0.000 claims description 2
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 claims description 2
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 2
- 101001046587 Homo sapiens Krueppel-like factor 1 Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 2
- 101000899339 Homo sapiens Lymphoid-specific helicase Proteins 0.000 claims description 2
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 claims description 2
- 101000624625 Homo sapiens M-phase inducer phosphatase 1 Proteins 0.000 claims description 2
- 101000624631 Homo sapiens M-phase inducer phosphatase 2 Proteins 0.000 claims description 2
- 101100238363 Homo sapiens MPRIP gene Proteins 0.000 claims description 2
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 101001005605 Homo sapiens Mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 claims description 2
- 101000577891 Homo sapiens Myeloid cell nuclear differentiation antigen Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001013159 Homo sapiens Myeloid leukemia factor 2 Proteins 0.000 claims description 2
- 101001128495 Homo sapiens Myeloid zinc finger 1 Proteins 0.000 claims description 2
- 101000581961 Homo sapiens Neurocalcin-delta Proteins 0.000 claims description 2
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 claims description 2
- 101000973200 Homo sapiens Nuclear factor 1 C-type Proteins 0.000 claims description 2
- 101001109512 Homo sapiens Nucleoplasmin-3 Proteins 0.000 claims description 2
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 claims description 2
- 101000601664 Homo sapiens Paired box protein Pax-8 Proteins 0.000 claims description 2
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 claims description 2
- 101000955481 Homo sapiens Phosphatidylcholine translocator ABCB4 Proteins 0.000 claims description 2
- 101000583474 Homo sapiens Phosphatidylinositol-binding clathrin assembly protein Proteins 0.000 claims description 2
- 101001129789 Homo sapiens Piezo-type mechanosensitive ion channel component 1 Proteins 0.000 claims description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 2
- 101000596119 Homo sapiens Plastin-3 Proteins 0.000 claims description 2
- 101000919019 Homo sapiens Probable ATP-dependent RNA helicase DDX6 Proteins 0.000 claims description 2
- 101000711369 Homo sapiens Probable ribosome biogenesis protein RLP24 Proteins 0.000 claims description 2
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 claims description 2
- 101001124667 Homo sapiens Proteasome subunit alpha type-5 Proteins 0.000 claims description 2
- 101000898093 Homo sapiens Protein C-ets-2 Proteins 0.000 claims description 2
- 101000947115 Homo sapiens Protein CASC3 Proteins 0.000 claims description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 claims description 2
- 101000912957 Homo sapiens Protein DEK Proteins 0.000 claims description 2
- 101000781950 Homo sapiens Protein Wnt-16 Proteins 0.000 claims description 2
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 claims description 2
- 101000900789 Homo sapiens Protein canopy homolog 2 Proteins 0.000 claims description 2
- 101000861587 Homo sapiens Protein farnesyltransferase subunit beta Proteins 0.000 claims description 2
- 101000971404 Homo sapiens Protein kinase C iota type Proteins 0.000 claims description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 claims description 2
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims description 2
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 claims description 2
- 101000979900 Homo sapiens Putative methyltransferase NSUN5C Proteins 0.000 claims description 2
- 101000926083 Homo sapiens Rab GDP dissociation inhibitor beta Proteins 0.000 claims description 2
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 claims description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 2
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 claims description 2
- 101000752221 Homo sapiens Rho guanine nucleotide exchange factor 2 Proteins 0.000 claims description 2
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 claims description 2
- 101000701876 Homo sapiens Serpin A9 Proteins 0.000 claims description 2
- 101000643374 Homo sapiens Serrate RNA effector molecule homolog Proteins 0.000 claims description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
- 101000648553 Homo sapiens Sushi domain-containing protein 6 Proteins 0.000 claims description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 2
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 claims description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000653469 Homo sapiens T-complex protein 1 subunit zeta Proteins 0.000 claims description 2
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims description 2
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 claims description 2
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims description 2
- 101000653540 Homo sapiens Transcription factor 7 Proteins 0.000 claims description 2
- 101000596772 Homo sapiens Transcription factor 7-like 1 Proteins 0.000 claims description 2
- 101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 claims description 2
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 claims description 2
- 101001057127 Homo sapiens Transcription factor ETV7 Proteins 0.000 claims description 2
- 101001028730 Homo sapiens Transcription factor JunB Proteins 0.000 claims description 2
- 101000979190 Homo sapiens Transcription factor MafB Proteins 0.000 claims description 2
- 101001057681 Homo sapiens Translation initiation factor eIF-2B subunit beta Proteins 0.000 claims description 2
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims description 2
- 101000611185 Homo sapiens Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 claims description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101001009087 Homo sapiens Tyrosine-protein kinase HCK Proteins 0.000 claims description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 2
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 claims description 2
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 2
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 claims description 2
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 101000708874 Homo sapiens Zinc finger protein ubi-d4 Proteins 0.000 claims description 2
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 claims description 2
- 108010007666 IMP cyclohydrolase Proteins 0.000 claims description 2
- 102100023747 Immunoglobulin lambda variable 6-57 Human genes 0.000 claims description 2
- 102100020796 Inosine 5'-monophosphate cyclohydrolase Human genes 0.000 claims description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 2
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims description 2
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 claims description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 claims description 2
- 102100032819 Integrin alpha-3 Human genes 0.000 claims description 2
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 2
- 102100032817 Integrin alpha-5 Human genes 0.000 claims description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 2
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims description 2
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 2
- 102100029838 Interferon regulatory factor 2 Human genes 0.000 claims description 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims description 2
- 102100039060 Interleukin enhancer-binding factor 2 Human genes 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- 102100033501 Interleukin-32 Human genes 0.000 claims description 2
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 102100022248 Krueppel-like factor 1 Human genes 0.000 claims description 2
- 108010025026 Ku Autoantigen Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 102100038204 Large neutral amino acids transporter small subunit 1 Human genes 0.000 claims description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 2
- 102100022539 Lymphoid-specific helicase Human genes 0.000 claims description 2
- 102100033468 Lysozyme C Human genes 0.000 claims description 2
- 102100023326 M-phase inducer phosphatase 1 Human genes 0.000 claims description 2
- 102100023325 M-phase inducer phosphatase 2 Human genes 0.000 claims description 2
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 claims description 2
- 101150117406 Mafk gene Proteins 0.000 claims description 2
- 102100030417 Matrilysin Human genes 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 101100273286 Mus musculus Casp4 gene Proteins 0.000 claims description 2
- 101100242031 Mus musculus Pdha2 gene Proteins 0.000 claims description 2
- 102100034681 Myeloblastin Human genes 0.000 claims description 2
- 102100027994 Myeloid cell nuclear differentiation antigen Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100029687 Myeloid leukemia factor 2 Human genes 0.000 claims description 2
- 102100031827 Myeloid zinc finger 1 Human genes 0.000 claims description 2
- 102100037183 Myosin phosphatase Rho-interacting protein Human genes 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 102100027348 Neurocalcin-delta Human genes 0.000 claims description 2
- 102100030411 Neutrophil collagenase Human genes 0.000 claims description 2
- 108700031302 Nuclear Factor 45 Proteins 0.000 claims description 2
- 102100022162 Nuclear factor 1 C-type Human genes 0.000 claims description 2
- 102100022684 Nucleoplasmin-3 Human genes 0.000 claims description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 claims description 2
- 102000036673 PRAME Human genes 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 2
- 102100037504 Paired box protein Pax-5 Human genes 0.000 claims description 2
- 102100037506 Paired box protein Pax-6 Human genes 0.000 claims description 2
- 102100037502 Paired box protein Pax-8 Human genes 0.000 claims description 2
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 claims description 2
- 102100039032 Phosphatidylcholine translocator ABCB4 Human genes 0.000 claims description 2
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 claims description 2
- 102100031014 Phosphatidylinositol-binding clathrin assembly protein Human genes 0.000 claims description 2
- 102100031693 Piezo-type mechanosensitive ion channel component 1 Human genes 0.000 claims description 2
- 102100035220 Plastin-3 Human genes 0.000 claims description 2
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 2
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims description 2
- 102100040169 Pre-B-cell leukemia transcription factor 3 Human genes 0.000 claims description 2
- 102100029480 Probable ATP-dependent RNA helicase DDX6 Human genes 0.000 claims description 2
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 claims description 2
- 102100029270 Proteasome subunit alpha type-5 Human genes 0.000 claims description 2
- 102100021890 Protein C-ets-2 Human genes 0.000 claims description 2
- 102100035601 Protein CASC3 Human genes 0.000 claims description 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims description 2
- 102100026113 Protein DEK Human genes 0.000 claims description 2
- 108010015499 Protein Kinase C-theta Proteins 0.000 claims description 2
- 102100036587 Protein Wnt-16 Human genes 0.000 claims description 2
- 102100027584 Protein c-Fos Human genes 0.000 claims description 2
- 102100022050 Protein canopy homolog 2 Human genes 0.000 claims description 2
- 102100027569 Protein farnesyltransferase subunit beta Human genes 0.000 claims description 2
- 102100021557 Protein kinase C iota type Human genes 0.000 claims description 2
- 102100021566 Protein kinase C theta type Human genes 0.000 claims description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 claims description 2
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims description 2
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims description 2
- 102100024551 Putative methyltransferase NSUN5C Human genes 0.000 claims description 2
- 102000001195 RAD51 Human genes 0.000 claims description 2
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims description 2
- 108090000292 RNA-binding protein FUS Proteins 0.000 claims description 2
- 102100034328 Rab GDP dissociation inhibitor beta Human genes 0.000 claims description 2
- 108010068097 Rad51 Recombinase Proteins 0.000 claims description 2
- 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 claims description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 2
- 108010071034 Retinoblastoma-Binding Protein 4 Proteins 0.000 claims description 2
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 claims description 2
- 102100021707 Rho guanine nucleotide exchange factor 2 Human genes 0.000 claims description 2
- 102100023876 Rhombotin-2 Human genes 0.000 claims description 2
- 108010005173 SERPIN-B5 Proteins 0.000 claims description 2
- 108091006232 SLC7A5 Proteins 0.000 claims description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 2
- 101150063267 STAT5B gene Proteins 0.000 claims description 2
- 102100030420 Serpin A9 Human genes 0.000 claims description 2
- 102100030333 Serpin B5 Human genes 0.000 claims description 2
- 102100035712 Serrate RNA effector molecule homolog Human genes 0.000 claims description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 2
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 102100028858 Sushi domain-containing protein 6 Human genes 0.000 claims description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 2
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 claims description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100030664 T-complex protein 1 subunit zeta Human genes 0.000 claims description 2
- 101000874827 Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8) Dephospho-CoA kinase Proteins 0.000 claims description 2
- 102100034195 Thrombopoietin Human genes 0.000 claims description 2
- 102100034196 Thrombopoietin receptor Human genes 0.000 claims description 2
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims description 2
- 102100030627 Transcription factor 7 Human genes 0.000 claims description 2
- 102100038313 Transcription factor E2-alpha Human genes 0.000 claims description 2
- 102100039580 Transcription factor ETV6 Human genes 0.000 claims description 2
- 102100027263 Transcription factor ETV7 Human genes 0.000 claims description 2
- 102100037168 Transcription factor JunB Human genes 0.000 claims description 2
- 102100023234 Transcription factor MafB Human genes 0.000 claims description 2
- 102100039190 Transcription factor MafK Human genes 0.000 claims description 2
- 102100027065 Translation initiation factor eIF-2B subunit beta Human genes 0.000 claims description 2
- 108010091356 Tumor Protein p73 Proteins 0.000 claims description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100030018 Tumor protein p73 Human genes 0.000 claims description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 2
- 102100027389 Tyrosine-protein kinase HCK Human genes 0.000 claims description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 2
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 claims description 2
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 claims description 2
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 claims description 2
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 108700031763 Xeroderma Pigmentosum Group D Proteins 0.000 claims description 2
- 102100032701 Zinc finger protein ubi-d4 Human genes 0.000 claims description 2
- 108700000711 bcl-X Proteins 0.000 claims description 2
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 claims description 2
- 108010002712 deoxyribonuclease II Proteins 0.000 claims description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 2
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 238000000249 far-infrared magnetic resonance spectroscopy Methods 0.000 claims description 2
- 101150095658 ilf2 gene Proteins 0.000 claims description 2
- 108010019813 leptin receptors Proteins 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 108010064131 neuronal Cdk5 activator (p25-p35) Proteins 0.000 claims description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 2
- 238000004886 process control Methods 0.000 claims description 2
- 108010051009 proto-oncogene protein Pbx3 Proteins 0.000 claims description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 102100037711 Developmentally-regulated GTP-binding protein 2 Human genes 0.000 claims 6
- 101000880940 Homo sapiens Developmentally-regulated GTP-binding protein 2 Proteins 0.000 claims 6
- 208000027393 severe congenital neutropenia 5 Diseases 0.000 claims 4
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 claims 2
- 102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102100023247 60S ribosomal protein L23a Human genes 0.000 claims 1
- 102100040743 Alpha-crystallin B chain Human genes 0.000 claims 1
- 102100033658 Alpha-globin transcription factor CP2 Human genes 0.000 claims 1
- 108700024832 B-Cell CLL-Lymphoma 10 Proteins 0.000 claims 1
- 102100021570 B-cell lymphoma 3 protein Human genes 0.000 claims 1
- 102100037598 B-cell lymphoma/leukemia 10 Human genes 0.000 claims 1
- 101150074953 BCL10 gene Proteins 0.000 claims 1
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 claims 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 claims 1
- 101150104237 Birc3 gene Proteins 0.000 claims 1
- 102100021975 CREB-binding protein Human genes 0.000 claims 1
- 101000879203 Caenorhabditis elegans Small ubiquitin-related modifier Proteins 0.000 claims 1
- 102100033773 Collagen alpha-6(IV) chain Human genes 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 claims 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 102220482610 E3 ubiquitin-protein ligase DCST1_P55G_mutation Human genes 0.000 claims 1
- 102100039247 ETS-related transcription factor Elf-4 Human genes 0.000 claims 1
- 108010055191 EphA3 Receptor Proteins 0.000 claims 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 102100023734 G protein-coupled receptor kinase 4 Human genes 0.000 claims 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 claims 1
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 claims 1
- 101000806242 Homo sapiens 17-beta-hydroxysteroid dehydrogenase type 1 Proteins 0.000 claims 1
- 101000682512 Homo sapiens 60S ribosomal protein L17 Proteins 0.000 claims 1
- 101001115494 Homo sapiens 60S ribosomal protein L23a Proteins 0.000 claims 1
- 101000891982 Homo sapiens Alpha-crystallin B chain Proteins 0.000 claims 1
- 101000800875 Homo sapiens Alpha-globin transcription factor CP2 Proteins 0.000 claims 1
- 101100275686 Homo sapiens CR2 gene Proteins 0.000 claims 1
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 claims 1
- 101000710885 Homo sapiens Collagen alpha-6(IV) chain Proteins 0.000 claims 1
- 101000800646 Homo sapiens DNA nucleotidylexotransferase Proteins 0.000 claims 1
- 101000865099 Homo sapiens DNA-directed DNA/RNA polymerase mu Proteins 0.000 claims 1
- 101000813135 Homo sapiens ETS-related transcription factor Elf-4 Proteins 0.000 claims 1
- 101000829481 Homo sapiens G protein-coupled receptor kinase 4 Proteins 0.000 claims 1
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101001106090 Homo sapiens Receptor expression-enhancing protein 5 Proteins 0.000 claims 1
- 101000657845 Homo sapiens Small nuclear ribonucleoprotein-associated proteins B and B' Proteins 0.000 claims 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 1
- 101000766349 Homo sapiens Tribbles homolog 2 Proteins 0.000 claims 1
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 claims 1
- 101000912503 Homo sapiens Tyrosine-protein kinase Fgr Proteins 0.000 claims 1
- 102100031775 Leptin receptor Human genes 0.000 claims 1
- 101100275687 Mus musculus Cr2 gene Proteins 0.000 claims 1
- 101100010166 Mus musculus Dok3 gene Proteins 0.000 claims 1
- 101100387128 Myxococcus xanthus (strain DK1622) devR gene Proteins 0.000 claims 1
- 102100039614 Nuclear receptor ROR-alpha Human genes 0.000 claims 1
- 101100502853 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) fkl gene Proteins 0.000 claims 1
- 101150098638 RNASE1 gene Proteins 0.000 claims 1
- 102100021077 Receptor expression-enhancing protein 5 Human genes 0.000 claims 1
- 102100039832 Ribonuclease pancreatic Human genes 0.000 claims 1
- 102000051619 SUMO-1 Human genes 0.000 claims 1
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 claims 1
- 102100034683 Small nuclear ribonucleoprotein-associated proteins B and B' Human genes 0.000 claims 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 claims 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 102100026394 Tribbles homolog 2 Human genes 0.000 claims 1
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 claims 1
- 102100026150 Tyrosine-protein kinase Fgr Human genes 0.000 claims 1
- 102100036973 X-ray repair cross-complementing protein 5 Human genes 0.000 claims 1
- UORJNBVJVRLXMQ-UHFFFAOYSA-N aprobarbital Chemical compound C=CCC1(C(C)C)C(=O)NC(=O)NC1=O UORJNBVJVRLXMQ-UHFFFAOYSA-N 0.000 claims 1
- 101150044165 cas7 gene Proteins 0.000 claims 1
- CZWHMRTTWFJMBC-UHFFFAOYSA-N dinaphtho[2,3-b:2',3'-f]thieno[3,2-b]thiophene Chemical compound C1=CC=C2C=C(SC=3C4=CC5=CC=CC=C5C=C4SC=33)C3=CC2=C1 CZWHMRTTWFJMBC-UHFFFAOYSA-N 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 claims 1
- 101150076131 rib-1 gene Proteins 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 7
- 230000006870 function Effects 0.000 description 49
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
- 230000004069 differentiation Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 238000011282 treatment Methods 0.000 description 17
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 16
- 230000006399 behavior Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 206010025323 Lymphomas Diseases 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000013456 study Methods 0.000 description 13
- 238000012549 training Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 108020004635 Complementary DNA Proteins 0.000 description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 11
- 238000010804 cDNA synthesis Methods 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000011132 hemopoiesis Effects 0.000 description 10
- 230000000877 morphologic effect Effects 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000010200 validation analysis Methods 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000004077 genetic alteration Effects 0.000 description 7
- 231100000118 genetic alteration Toxicity 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000002071 myeloproliferative effect Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000003491 array Methods 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000007405 data analysis Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
- 208000019420 lymphoid neoplasm Diseases 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000000528 statistical test Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 206010000830 Acute leukaemia Diseases 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 102100026548 Caspase-8 Human genes 0.000 description 5
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 210000003563 lymphoid tissue Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 206010028537 myelofibrosis Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010058314 Dysplasia Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 208000034951 Genetic Translocation Diseases 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108700020978 Proto-Oncogene Proteins 0.000 description 4
- 102000052575 Proto-Oncogene Human genes 0.000 description 4
- 208000009527 Refractory anemia Diseases 0.000 description 4
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000002559 cytogenic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 208000004860 Blast Crisis Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000010802 RNA extraction kit Methods 0.000 description 3
- 208000035977 Rare disease Diseases 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000002790 cross-validation Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 208000037244 polycythemia vera Diseases 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MZWGYEJOZNRLQE-KXQOOQHDSA-N 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC MZWGYEJOZNRLQE-KXQOOQHDSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000723784 Plum pox virus Species 0.000 description 2
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 description 2
- 208000005485 Thrombocytosis Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000008711 chromosomal rearrangement Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 210000004214 philadelphia chromosome Anatomy 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012956 testing procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 102000052666 B-Cell Lymphoma 3 Human genes 0.000 description 1
- 208000037398 BCR-ABL1 negative atypical chronic myeloid leukemia Diseases 0.000 description 1
- 206010004173 Basophilia Diseases 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 102100026031 Beta-glucuronidase Human genes 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100021633 Cathepsin B Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100031621 Cysteine and glycine-rich protein 2 Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100039301 DNA-directed RNA polymerase II subunit RPB3 Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241001050985 Disco Species 0.000 description 1
- 102100020767 Dystrophin-related protein 2 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101150038592 GAPD gene Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100030386 Granzyme A Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 102100034864 Homeobox protein Hox-D9 Human genes 0.000 description 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 description 1
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 1
- 101000940752 Homo sapiens Cysteine and glycine-rich protein 2 Proteins 0.000 description 1
- 101000669859 Homo sapiens DNA-directed RNA polymerase II subunit RPB3 Proteins 0.000 description 1
- 101001053503 Homo sapiens Dihydropyrimidinase-related protein 2 Proteins 0.000 description 1
- 101000931797 Homo sapiens Dystrophin-related protein 2 Proteins 0.000 description 1
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 1
- 101001019766 Homo sapiens Homeobox protein Hox-D9 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101001060736 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP1B Proteins 0.000 description 1
- 101001031398 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP9 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001132698 Homo sapiens Retinoic acid receptor beta Proteins 0.000 description 1
- 101000951145 Homo sapiens Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Proteins 0.000 description 1
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 1
- 101000652726 Homo sapiens Transgelin-2 Proteins 0.000 description 1
- 101000777263 Homo sapiens UV radiation resistance-associated gene protein Proteins 0.000 description 1
- 101000807354 Homo sapiens Ubiquitin-conjugating enzyme E2 C Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 102000043138 IRF family Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000015335 Ku Autoantigen Human genes 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 102100029825 Leptin receptor gene-related protein Human genes 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 1
- 208000033495 Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality Diseases 0.000 description 1
- 206010067387 Myelodysplastic syndrome transformation Diseases 0.000 description 1
- 208000037379 Myeloid Chronic Atypical BCR-ABL Negative Leukemia Diseases 0.000 description 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 101150040560 POU2F2 gene Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102100038809 Peptidyl-prolyl cis-trans isomerase FKBP9 Human genes 0.000 description 1
- 206010073391 Platelet dysfunction Diseases 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 102100023089 Protein S100-A2 Human genes 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 241001417495 Serranidae Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 102100038014 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Human genes 0.000 description 1
- 241000306287 Sweet potato pakakuy virus Species 0.000 description 1
- 108700012457 TACSTD2 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 1
- 102100031016 Transgelin-2 Human genes 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 1
- 102100031275 UV radiation resistance-associated gene protein Human genes 0.000 description 1
- 102100037256 Ubiquitin-conjugating enzyme E2 C Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008578 acute process Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 201000004892 atypical chronic myeloid leukemia Diseases 0.000 description 1
- 208000013130 autosomal recessive severe congenital neutropenia due to G6PC3 deficiency Diseases 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000003053 chromosome 5q deletion syndrome Diseases 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000006650 fundamental cellular process Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000579 hyperploidy effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000005741 malignant process Effects 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000001785 maturational effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 108091008796 oncogenic growth factors Proteins 0.000 description 1
- 230000008266 oncogenic mechanism Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108010036550 osteoclast activating factor Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 101150110928 psmb4 gene Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023933 refractory anemia with excess blasts in transformation Diseases 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000034380 severe congenital 9 autosomal dominant neutropenia Diseases 0.000 description 1
- 208000027397 severe congenital neutropenia 4 Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the invention is attached to the technical-industrial sector of in vitro, extracorporeal diagnosis of biological samples, by means of genetic engineering techniques, applied to the diagnosis of specific types of neoplasms from their gene expression patterns and / or to the prognosis of their evolution. . More specifically, the invention relates to the identification of neoplasms originating from hematopoietic cells from the evaluation of messenger RNA levels of significant genes in biological samples such as peripheral blood samples, preferably by the use of microarrays. .
- samples corresponding to patients suffering from CLL can be identified, allowing the diagnosis of the same and, in addition, samples from patients suffering from CLL can be classified into samples belonging to patients in whom the CLL will remain stable or in which to progress, allowing the prognosis of the future evolution of these patients.
- hematopoiesis Weissman IL et al, 2000; Leung AYH et al, 2005).
- hematopoiesis is confined to the bone marrow (MO) of most bones, and gradually, with age, it is replaced by fat so that, in adults, 70% of the bone marrow Bone is located in the pelvis, vertebrae and sternum (Bernard et al, 1976).
- All mature blood cells are generated from a relatively low number of hematopoietic cells known as stem or stem stem cells.
- the hematopoietic stem cell has two characteristics that are the pluripotentiality or ability to give rise to the different hematopoietic cell lines and the self-renewal or property of perpetuating generating cells equal to itself (Weissman IL et al, 2000). This ability is essential for the maintenance of hematopoiesis throughout life since, without self-renewal, the stock of available stem cells would be rapidly depleted.
- Hematopoietic stem cells are capable of generating different mature hematopoietic cell types through a series of progenitors and intermediate precursors.
- the differentiation of hematopoietic cells implies changes that affect, among others, the size and shape of the cell, the expression of genes, proteins, signal response and cell location.
- Terminal differentiated cells have lost their ability to divide and suffer apoptosis after a period of time ranging from hours for neutrophils to decades for some lymphocytes. This fact makes the M.O. must constantly ensure cell turnover (Datta SR et al, 1999).
- the hematopoiesis process comprises a complex interaction between intrinsic genetic events of the hematopoietic cells and the environment in which they are found. This interaction is what determines whether hematopoietic precursors and progenitors should remain quiescent, proliferate, differentiate in one line or another or enter apoptosis (Domen J et al, 1999). All the genetic and environmental mechanisms that govern the production of blood cells operate by altering the relative balance of these fundamental cellular processes.
- Hematologic malignancies are malignant processes that affect any of the cell types involved in the hematopoietic system. As a consequence of this transformation, the cell is blocked in a stage of differentiation and begins to accumulate due to uncontrolled proliferation, a failure of the apoptotic mechanism or a blockage of its differentiation process.
- neoplasms The malignant transformation of hematopoietic cells during the different stages through which they go through differentiation into mature cells causes a large number of different neoplasms (Guttmacher AE et al., 2003). This type of neoplasms is therefore a very heterogeneous group of diseases that only have in common the hematopoietic origin of the transformed cell type.
- lymphoid neoplasms that affect the different cell types and maturational degrees that make up the lymphoid line both B and T
- myeloid neoplasms that affect various cell types of the myeloid line.
- leukemias have been differentiated arbitrarily from lymphomas, pointing to leukemias as those neoplasms that affect the bone marrow and have peripheral expression, that is, circulation of abnormal cells in blood, and lymphomas such as those neoplasms that remain located in the lymph nodes or other lymphoid tissues and that lack, at least initially, leukemic behavior.
- lymphomas such as those neoplasms that remain located in the lymph nodes or other lymphoid tissues and that lack, at least initially, leukemic behavior.
- acute and chronic processes have been differentiated initially by the morpho-cytological characteristics of proliferating cells (immature and atypical in the first case and more differentiated in the second) and to the clinical manifestations of the disease.
- the knowledge of immunological markers and genetic alterations that affect hematopoietic cells help to differentiate with different precision the different processes.
- the REAL classification system unlike other previous classification systems, is based on the definition of "real" entities and not on morphological subtypes. For the establishment of these "real” entities, all available information is used, that is, morphological, immunophenotypic and biological data are combined with genetic and clinical characteristics (Harris NL et al, 1999a).
- the WHO classification which was presented in 1997, stratifies the entities according to the affected cell line: myeloid, lymphoid, histiocytic / dendritic and mastocytic. Within each category, the disease is defined according to morphology, immunophenotype, genetic and clinical data (Harris NL et al, 1999b). In many neoplasms, the stage in which the accumulated tumor cell is not coincides with the stage in which the initial transforming event occurred. Thus, many hematological malignancies originate in the initial precursors and the specific genetic alteration can determine that the cell continues to advance in its differentiation until it stops and accumulates in more advanced stages of differentiation (Shaffer AL et al, 2002).
- neoplasms can develop in the most advanced stages of differentiation, as occurs in cells from the follicular center in which genetic translocations and rearrangements produce activation of genes that contribute to tumor development.
- the nomenclature for each entity reflects the best estimate for its cell line and stage of differentiation, recognizing that the knowledge currently available is imperfect and that changes in the allocation to the cell line and in the nomenclature may occur as the available knowledge.
- Morphological evaluation of the cell Microscopic observation of the cells involved. Information is obtained on the type of cell and degree of maturation in which it is found.
- Immunophenotype study Recognition of antigens expressed on the surface of the neoplastic cell. These antigens are expressed differently and to a different degree depending on the lineage and the stage in which the cell is located.
- the expression of characteristic surface antigens of the line and stage of differentiation in which the cell is found is known, for example, the expression of CD 19 and CD20 is typical of B-line cells, while the expression of CD3 is typical of line T.
- the study of CD23 is key when differentiating LNHCM from LLC (Gong JZ et al, 2001).
- the WHO establishes four large groups of hematological malignancies based on the lineage involved (myeloid, lymphoid, histiocytic / dendritic and mastocytic neoplasms).
- the neoplasms belonging to the myeloid and lymphoid line are described below with greater amplitude because they occur most frequently.
- Those corresponding to the histiocytic / dendritic and mastocytic lines at the moment constitute very specific entities.
- SMP Myeloproliferative syndromes
- SMPC Chronic myeloproliferative syndromes
- CML Chronic myeloid leukemia
- the CML has a low incidence of approximately one case per 100,000 inhabitants / year and appears more frequently in the fifth and sixth decade of life. It can be considered as a rare disease.
- CMLL chronic myelomonocytic leukemia
- the diagnosis is based on elevated cell counts for the white series, appearance of morphologically normal myeloid cells and at all stages of differentiation, but with a high number of myelocytes and neutrophils, there is usually basophilia and thrombocytosis.
- the predominant cell is myeloblast (65%) or lymphoblast (35%).
- Polycythemia vera is a benign hematological disease, the condition of which does not influence the shortening of survival. However, it is a clonal disease that can evolve in 15% of patients to myelofibrosis or acute leukemia (5%).
- TE Essential Thrombocythemia
- MF Myelofibrosis
- MS Systemic mastocytosis
- SMD Myelodysplastic / Myeloproliferative Syndromes
- Myelodysplastic syndromes are clonal proliferations of the hematopoietic stem cell that share clinical, morphological and analytical data that overlap between LAM and SMPC at the time of diagnosis. They are characterized by the hypercellularity of the bone marrow due to the proliferation of one or more myeloid lines (Heaney ML, 1999). The presence of dysplasia in at least one line (myeloid, erythroid or megakaryocytic-platelet) is a characteristic of MDS. The incidence is variable depending on the variety. An incidence of 3 cases per 100,000 inhabitants over 60 years / year is estimated.
- the FAB classification establishes 4 diagnostic categories (Bennett JM et al., 1984): simple refractory anemia (RA), refractory anemia with ring sideroblasts (ARS), refractory anemia with excess blasts (AREB) and refractory anemia with excess blasts in transformation (AREB-T) and chronic myelomonocytic leukemia (CMML).
- RA simple refractory anemia
- ARS refractory anemia with ring sideroblasts
- AREB refractory anemia with excess blasts
- AREB-T chronic myelomonocytic leukemia
- WHO establishes five different categories (Harris NL, et al., 1999): refractory anemia, refractory cytopenia with multilinear dysplasia, refractory anemia with excess blasts, unclassifiable MDS, and MDS associated with an isolated defect on chromosome 5 (of 5q) or 5q- syndrome.
- LAM Acute Myeloblastic Leukemia
- the WHO classifies the LAM incorporating morphological data, immunophenotypic, genetic and clinical characteristics to be able to define biologically homogeneous entities and with clinical relevance.
- LAM is classified into four broad categories: 1.- LAM with recurrent genetic abnormalities. 2.- LAM with multilinear dysplasia. 3.- LAM related to treatment and 4.- LAM not classifiable (ref WHO).
- the first three categories recognize the importance of biological factors that predict the evolution of the process. Cytogenetic analysis represents the most powerful prognostic factor (Roumier C, et al, 2003).
- the medullary image in the microscopic examination of the aspirate is generally that of an invasion by cells similar to each other, of immature morphological characteristics that distort the normal cellular distribution constituting authentic cell sheets.
- the medullary hyperproduction determines that areas of inactive bone marrow in adulthood again return to hematopoiesis foci, in this case of abnormal cells.
- the WHO classification is a refinement of the REAL classification (Harris NL et al. 1994).
- Three large groups of lymphoid neoplasms are recognized: 1.- Lymphoid neoplasms derived from B cells. 2.- Lymphoid neoplasms derived from T and NK cells. 3.- Hodgkin lymphoma.
- This classification includes solid neoplasms and lymphoid leukemias because in many of them there is a transformation from one phase to another and the distinction between them can be artificial.
- chronic B lymphatic leukemia and lymphocytic NHL are caused by the same cell and simply represent different manifestations of the same neoplasm, the same occurs with lymphoblastic lymphoma and lymphoblastic leukemia.
- the WHO classification divides these neoplasms according to the stage of maturation in which the cells are found in precursor cell neoplasms and mature cell neoplasms (WHO Classification Tumors of Haematopoietic and lymphoid tissues.
- WHO Classification Tumors of Haematopoietic and lymphoid tissues In Pathology an genetics of tumours of Haematopoietic and lymphoid tissues, ES Jaffe, NL Harris, H Stein, JW Vardiman, IARC Press, Lyon, 2001). Due to the high number of entities described, the following stand out:
- ALL Acute lymphoblastic leukemia
- the overall appearance of the bone marrow is similar to that described for myeloid leukemia.
- the investigation of minimal residual disease is important, a factor that conditions the probable relapse of the disease with its presence.
- the FAB classification defines 3 stages based on morphology (L1-L3).
- CLL Chronic lymphatic leukemia
- CLL is characterized by clonal proliferation and accumulation of lymphocytes with mature appearance and resistant to apoptosis in M.O., blood and lymphoid organs (Galton DA, 1966).
- lymphocytic lymphoma When lymphadenopathy is dominant, the clinical picture is called lymphocytic lymphoma. Affected lymphocytes are line B in 95% of cases and 5% of cases are involved T lymphocytes.
- the Binet classification (Binet JL et al, 1981) defines 3 stages of disease based on the hemoglobin concentration, number of platelets, number of nodes involved and the presence of visceromegalies.
- Rai's classification (Rai KR et al, 1975) uses the same indicators but classifies patients into five groups
- This neoplasm is not characterized by a single and recurring genomic alteration.
- markers that print a more unfavorable prognosis such as the presence of deletions on chromosomes 17 and 11 and those patients with absence of mutations in IgVh genes (40% of cases) and high proportion of cells expressing CD38 are characterized by a course more aggressive clinical and a worse response to treatment (Hamblin TJ et al, 1999; Durig J et al, 2002).
- Another recently described marker is ZAP-70, an independent prognostic marker whose expression is indirectly related to the mutational state of the immunoglobulin heavy chain gene (Crespo M et al,
- MM Multiple myeloma
- MM is a malignant disease in which a clone of plasma cells (terminal element of the lymphoid line B) of the bone marrow undergoes an uncontrolled proliferation. It accounts for 10-15% of all malignant diseases and is characteristic of advanced ages, only 2% of cases are diagnosed before age 40. For unknown reasons the incidence of the disease is increasing.
- the neoplastic plasma cell produces other molecules such as IL6, tumor necrosis factor or osteoclast activating factor that contribute to osteolysis, hypercalcemia and renal failure, characteristic alterations of the disease.
- the diagnosis can be accidental when performing an analysis in patients without symptoms or limited disease (20% of cases).
- the disease in these patients can remain stable for years and early treatment in the asymptomatic phase does not provide any advantage.
- MM monoclonal gammopathy of undetermined significance
- the monoclonal component can also be associated with other diseases such as lymphoma, non-hematological malignancies and connective tissue diseases.
- lymphoproliferative disease characterized by the infiltration of abnormal lymphoplasmocyte cells in the bone marrow, lymph nodes and spleen, accompanied by monoclonal production of immunoglobulin M, which determines an increase in blood viscosity and the appearance of hemorrhagic vascular manifestations and difficulty in circulation in small vessels.
- NHLs are solid tumors of lymphoid tissue much more heterogeneous than Hodgkin's disease.
- the complexity and diversity that NHLs have in terms of morphology, genetics, phenotype and clinical behavior has resulted in the existence of multiple classifications, none of them completely satisfactory.
- the clinical presentation of the disease is more irregular than in Hodgkin's disease. It can behave indolently without requiring immediate treatment or, conversely, behave aggressively quickly fatal.
- lymphatic tissue The diagnosis is made by histological study of lymphatic tissue. Additional information is obtained by monoclonal antibodies directed against specific lymphocyte antigens (immunophenotype); This helps to identify the degree of maturation of the malignant cell and determine the T or B origin of it. The presence of mutation in genes encoding Ig in NHL of strain B is usually used for the identification of some subtypes of NHL (Kuppers R et al, 1999). 2.2. Hodgkin lymphoma ⁇ LH)
- RS Reed-Sternberg
- Epstein-Barr virus DNA in the tumor has been detected.
- One hypothesis is that the bimodal distribution of the disease is due to infection in young subjects and the other peak would be caused by environmental causes.
- the diagnosis is obtained by biopsy of a lymph node. To plan the treatment it is necessary to determine the extent of the disease. (Rieppers R, 2002; Cossman J, 2001; Devilard E et al, 2002).
- variable clinical behavior Within the same category are patients whose disease will remain stable for a long period of time and who will not require therapy and others whose disease will progress rapidly requiring aggressive therapy.
- Expression arrays are ordered sets of sequences associated with a solid support, complementary to mRNA or their corresponding cDNA or cRNA, which allow the analysis of the differential expression of hundreds or thousands of genes simultaneously.
- a solid support complementary to mRNA or their corresponding cDNA or cRNA, which allow the analysis of the differential expression of hundreds or thousands of genes simultaneously.
- One of the supports to which these sequences are frequently attached is to rectangular glass fragments similar to the slides, a format that is often referred to by the terms "microarray”, “biochip” or simply “chip”. Its use is becoming increasingly frequent for the diagnosis of various diseases or for the evaluation of the susceptibility to suffer them.
- LDCGB diffuse large B cell lymphoma
- patent application WO2003 / 008552 describes the use for diagnostic purposes of differences in the pattern of gene expression to differentiate between mixed lineage leukemia (MLL), acute lymphoblastic leukemia (ALL) and myelogenous leukemia acute (AML), defending the possibility of making this differential diagnosis with the data obtained after the analysis of samples of patients afflicted with each of these types of leukemia through the use of commercial "chips" of Affymetrix.
- MLL mixed lineage leukemia
- ALL acute lymphoblastic leukemia
- AML myelogenous leukemia acute
- a method is described to obtain useful functions to predict the evolution of individuals affected by different types of lymphomas by evaluating in lymph node biopsies to what extent do they contribute to what they call gene patterns or footprints, groups of genes that are express in a coordinated way and that are related to the cellular origin of the neoplasm, the different types of Non-malignant cells present in the biopsy and oncogenic mechanisms responsible for cancer.
- the different patterns or gene prints are also deduced in this case from the data obtained with commercial chips from Affymetrix.
- the application WO2005 / 024043 claims to provide an alternative microarray, consisting of a smaller number of sequences than the Affymetrix microarrays, which would also allow the analysis of differences in gene expression between lymphomas and their application for the deduction of prediction functions of survival and for differentiation between different types of lymphomas.
- the genes whose analysis would be enabled by that microarray are indicated, the memory of the application WO2005 / 024043 does not indicate the sequence of the probes that would make up the microarray, mentioning only that they would be type cDNA and leaving doubts as to whether that cDNA would appear complete or the analysis of the expression of the corresponding gene would be performed using as a probe only a fragment of said cDNA, which would remain to be determined.
- compositions and methods that allow differentiation between hemopoietic neoplasms based on their molecular level differences, specifically designed for this group of neoplasms, in which the expression of a smaller number of genes was evaluated than in the Commercial microarrays used in the studies described in the aforementioned patent applications that will facilitate both the diagnosis of certain neoplasms and the prediction of their future evolution, thus helping in the prescription of a suitable treatment for each patient, a particularly interesting feature in those neoplasms, as is the case of CLL, in which the prognosis of the future evolution of the patient is difficult with the knowledge and trials available so far.
- probes used to evaluate the expression of the selected genes had been specifically designed so that, in addition to being specific and with a perfectly defined sequence, they all had similar behavior, which would make them appropriate, in general , to be used in combination in the same test and, in particular, to be part of the same array or array set associated with a solid support, such as the so-called “chips” or “microarrays”
- chips or “microarrays”
- the invention provides new oligonucleotides, of perfectly defined sequence, capable of specifically detecting genes that have been selected. for being known to be significant for the biology of blood cells or for the pathology of different neoplasms, oligonucleotides that also have the peculiarity of having been designed so that they share common characteristics that make them present a behavior similar to being used as probes in hybridization assays, which makes them suitable for use in compositions comprising combinations thereof.
- compositions and especially those in which these oligonucleotides are arranged in an orderly manner on an easy-to-use solid support such as slide-like glasses, are suitable for testing with which to detect statistically significant genes to differentiate samples taken from individuals.
- that suffer certain types of neoplasms originated from hematopoietic cells from samples taken from individuals who do not suffer from said neoplasms since they are compositions that contain a lower oligonucleotide number than commercial microarrays designed with a more general purpose, specifically designed for the analysis of samples from individuals suffering from neoplasms and being composed of probes of known sequence, perfectly reproducible, which are also specially designed to be used together in the same test because they are of similar behavior.
- microarrays of the invention allow the use of said microarrays for the identification of statistically significant genes in the identification of samples associated with certain hematopoietic neoplasms by means of the use of assays in which the establishment of controls in all its phases.
- the use of these microarrays in combination with various statistical techniques allows the correct classification of different biological samples by means of a precise, reproducible, easy-to-use method with biological significance.
- a microarray of the invention in combination with the method of the invention allows the identification of blood samples from patients suffering from chronic lymphatic leukemia (alteration not considered in applications WO2003 / 008552 and WO2005 / 024043 and whose diagnosis does not has been described through the use of commercial microarrays), distinguishing them both from samples obtained from healthy individuals and from samples related to other types of leukemia, such as those corresponding to Jurkat or U937 cells, facilitating the diagnosis of CLL through level analysis of expression of statistically significant genes for this and even allowing the obtaining of functions that allow the mathematical calculation of the probability that an unknown sample belongs to an individual afflicted with CLL.
- the invention allows differentiating samples belonging to individuals suffering from stable chronic lymphatic leukemia from samples belonging to individuals suffering from progressive chronic lymphatic leukemia, a distinction that is now difficult to perform a priori using the available techniques, which is a useful and novel tool for the prognosis of the future evolution of individuals afflicted with this disease, individuals whose diagnosis may also have been made by means of compositions and methods of the invention or may have been known thanks to the application of a different procedure, but for those who, having a tool that allows to predict how the LLC that they suffer will evolve later, it will be easier to decide if it is appropriate to undergo immediate aggressive treatment or simply keep them under periodic observation to verify that their gene expression data continues to indicate that the disease will remain stable for a long period of time. Summary of the invention
- compositions that include at least one oligonucleotide of the group consisting of:
- Said oligonucleotides have been designed so that, in addition to being specific for the corresponding genes whose expression is to be evaluated, they have a similar behavior, because they are of similar lengths and have all GC contents in the range of 40% to 60%. , in addition to corresponding to areas located less than 3000 nucleotides from the 3 '(poly (A)) end of the mRNA to be detected and evaluated and consisting of sequences that coincide in their sense with that of the corresponding mRNA. Therefore, they are suitable for use in the same test or to be part of a composition comprising combinations thereof.
- a particular embodiment of the invention is the compositions comprising mixtures of several of said oligonucleotides.
- compositions comprising oligonucleotide mixtures that correspond to significant genes to classify a sample as associated with a given neoplasm and / or to determine its future evolution.
- compositions comprising all the oligonucleotides of the group consisting of:
- the invention provides oligonucleotides useful for use as controls in the method of the invention.
- oligonucleotide pairs SG463 and SG464 (complementary, respectively to the 5 'and 3' ends of the ⁇ -actin gene) and SG466 and SG467 (complementary, respectively, to ends 5 are provided 'and 3' of the GAPD gene).
- oligonucleotides SSPCl, SSPC2, SSPC3, SSPC4, SSPC5, SSPC6 and SSPC7 are provided, which can be used as exogenous internal positive controls of process quality after added to the sample containing the starting mRNA polyadenylated nucleic acid molecules containing fragments that correspond in sequence with those of these oligonucleotides (such as transcripts corresponding to the genes from which said oligonucleotides are derived) and which are subjected to the same processing as the starting mRNA, as well as SCN2 oligonucleotides, SCN3, SCN6, SCN8, SCNI l, SCNl 2 and SCNl 3, designed to be used as positive controls for hybridization, and oligonucleotides SCNl, SCN5, SCN7, SCNlO, SCl, SC2, SC3, SC4, SC5, SC6 and SC7, designed to be used as negative controls; they all meet the conditions of presenting low homology with human
- composition containing at least one of the oligonucleotides SG463, SG464, SG466, SG467, SSPCl, SSPC2, SSPC3-, SSPC4, SSPC5, SSPC6, SSPC7, SCN2, SCN3, SCN6, SCN8, SCNI l, SCN12, SCN13, SCNl, SCN5, SCN7, SCN10, SCl, SC2, SC3, SC4, SC5, SC6 and SC7, in combination with at least one of the oligonucleotides complementary to human genes of the invention mentioned above is also a composition within the scope of the present invention .
- oligonucleotides that are part of a composition of the invention are attached to a solid support.
- those of such compositions are preferred in which the distribution of the oligonucleotides on the solid support are in an orderly manner, that the solid support used is a rectangular glass similar to the microscope slides and that the oligonucleotides are attached to the glass by covalent bonds;
- Compositions that fulfill such characteristics are referred to in the rest of the memory with the words "microarray", "chip” or "microchip”.
- compositions in the form of a microarray there is a special preference for those containing more than one copy of each of the oligonucleotides that are part of it, it being very especially preferred that the number of copies of each of the oligonucleotides present is of at least 12.
- diagnostic device refers not only to those that serve to determine whether or not an individual suffers from a disease, but those that serve to classify the disease that an individual suffers as belonging to a subtype associated with a particular form of evolution in the future of said disease and, therefore, also have prognostic value of the future evolution of the disease.
- the invention also provides a method for diagnosing a neoplasm originating from hematopoietic cells and / or predicting the evolution thereof comprising in vitro detection from a biological sample and statistical analysis of the level of expression of at least one gene. significant to classify the sample as associated or not to said neoplasm, a gene that is selected from the group consisting of GABARAP, NPM3, ABCBl, ABCB4, ABCC3, ABCC5, ABCC6, ABHDl, ABLl, ACTNl, AFIq, AKRlAl, ALDHlAl, ALK, ANK2 , ANPEP, ANXA6, ANXA7, APAFl, APEX, ARHGEF2, ARS2, ASNS, ATIC, ATM, ATP5O, BAX, BCLlO, BCL2, BCL2A1, BCL2L1, BCL2LAA, BCL3, BCL6, BCL7A, BCL7b, BCR, BCR, BCR, BCR,
- genes that are part of the group mentioned above are human genes. Therefore, whenever the words “subject” or “individual” are used hereafter, they shall refer to a human being.
- a particular case of this method is one that includes an additional previous stage of identification of significant genes for the classification of the biological sample analyzed as associated or not associated with a particular type of neoplasm originating from hematopoietic cells, classification in which It includes not only the diagnosis of the existence of said neoplasm in the individual from whom the sample has been extracted, but it can also consist, additionally or alternatively, in the discrimination between specific subtypes of said neoplasm that correspond to future forms of evolution of said different neoplasia, thus constituting the classification in one or another subtype a prognosis of the evolution of the neoplasm considered in the future.
- said previous stage comprises the sub-stages of: a) deciding the possible categories into which the sample can be classified; b) obtain biological samples from individuals that have previously been assigned by a different method to the one claimed in any of the possible classification categories, so that samples of each of the possible categories are available; c) obtain the total mRNA of each of the samples; d) obtain the corresponding total cRNA, marked by a method that allows its subsequent detection, of at least one aliquot of each of the mRNA samples, aliquot to which it is added before obtaining the cRNA at less a polyadenylated nucleotide sequence of low homology with human genes to act as an internal positive control of the process; e) add to each of the cRNA aliquots to be used in step f) at least one low homology oligonucleotide with human genes other than and not complementary to any possible nucleotide sequence added in
- microarray additionally comprising: a. at least two points corresponding to aliquots of the solvent in which the oligonucleotides were at the time of deposit on the surface of the microarray, to serve as a target, b.
- oligonucleotide for each of the polyadenylated sequences added in step d), oligonucleotide whose sequence will correspond to a fragment, other than the polyadenylation zone, of the polyadenylated nucleotide sequence whose evolution in the process must control; C. for each of the oligonucleotides added in step e), at least two copies of an oligonucleotide complementary thereto; d.
- each member of at least one oligonucleotide pair in which the sequence of one of the members corresponds to a sequence of the 5 'zone and the sequence of the other corresponds to a sequence of the 3' zone of the mRNA of a gene that is constitutively expressed in any cell of hematopoietic origin; and. at least two copies of at least one low homology oligonucleotide with human genes other than any of the oligonucleotides defined in section b.
- step e) detect and quantify the hybridized cRNA signal with each of the copies of each of the oligonucleotides present in the microarray, as well as the signal corresponding to the solvent points; h) calculate the average level of hybridization intensity of each of the oligonucleotides of the microarray by calculating the average of the intensities of the copies of each of the oligonucleotides; i) give hybridization as valid if the following conditions are met: to. the ratio between the average intensity and the average background of all oligonucleotides of the microarray is greater than 10; b.
- the mean coefficient of variation value of all oligonucleotide replicas must be less than 0.3; C. the average negative control value must be less than 2.5 times the average value of the points corresponding to the solvent; d. there is a signal both in the hybridization controls and in the internal positive controls used as process control; j) normalize the data; k) eliminate oligonucleotides with average intensity values less average background noise less than about 2 times the average value obtained with the points corresponding to the solvent, as well as oligonucleotides with an interquartile range of normalized intensity throughout the samples less than 0.3;
- the average value calculated in section h) is a bounded average, for which it is preferable that the microarray comprises at least four copies of each of the oligonucleotides present therein.
- Normalization can be done with different methods. There is a preference for the use of functions contained in free access packages through Internet designed for manipulation, calculation and graphic representation of data, such as packages designed for the R programming language, available for download from CRAN (http: //cran.r-project.orq/) or Bioconductor (http: //www.bioconductor.orq). Especially preferred is the "variance stabilization normalization" method available in the "vsn" package of R.
- the identification of the statistically significant oligonucleotides to differentiate between the different categories can be done by different methods, having preference for those in which a p-value is determined that determines the probability threshold below which all genes whose expression difference has a lower value ap would be considered significant and, among these, those that have the capacity to make corrections on the value of p, such as, among others, the Bonferroni method or the Welch test.
- the value of p will be chosen from the open range of O to 0.05, preferring, when possible, p values close to 0.001 and with correction, which value may be increased up to 0.05 (value that is not included among the possible) until statistically significant oligonucleotides are found to differentiate between the categories among which the samples are to be classified.
- Another possibility for the identification of statistically significant oligonucleotides to be able to differentiate between the established sample categories is the use of the "closest shrunken centroid" method, a variation of the “nearest centroid” method (Tibshirani et al, 2002), which identifies a group of genes that best characterizes a predefined class and uses this group of genes to predict the class to which new samples belong.
- functions contained in open access packages on the Internet can be used again, such as the "pam a " package of R, in which functions can be found to perform the so-called “Prediction Analysis for Microarrays (PAM)", which makes use of the "closest shrunken centroid” method.
- PAM Prediction Analysis for Microarrays
- the statistically significant genes can be used to classify new samples by similarity between the expression profile of those genes in the analyzed sample and the one corresponding to each of the categories of classification.
- the possible classification categories are only 2 (which will be normal when you want to diagnose the presence or absence of a certain type of leukemia in an individual)
- a mathematical function of classification of samples can be obtained that determines the value of the probability "pi" that a sample "i" belongs to one or another category.
- a subset of the samples that have been previously assigned to each of the possible categories is chosen by a different method from the invention and the value 0 is arbitrarily associated with the probability corresponding to each of the samples of one of the "a" categories (usually the category of "not associated with the leukemia to be diagnosed") of belonging to the other possible category, while each of the samples of the subset belonging to the other possible category "b" (usually, the category of "associated with the leukemia that is to be diagnosed”) arbitrarily receives the value "1" for its probability of belonging to its own category.
- logistic regression is used to calculate, with the help of the probability values assigned to each of the samples and the normalized mean intensity values obtained for each of the samples with each of the "n" oligonucleotides that are available. been identified as a statistically significant oligonucleotide in the previous stage, coefficients for each of said oligonucleotides that allow obtaining a probability function p that a sample "i" belongs to the category 'T) ", a function that will be of the type
- Imni oligm represents the average value of normalized intensity obtained in the hybridization of the sample i calculated for the oligonucleotide "m"
- n is the total number of oligonucleotides considered significant
- the function p ⁇ obtained after calculating by logistic regression the coefficient corresponding to each oligonucleotide allows to classify a sample "i" as belonging to one or another category, considering that p values greater than 0.5 (and that they will be less than or equal to 0) indicate that the sample belongs to category 'T) ", while p values less than 0.5 indicate that the Sample belongs to category "a”.
- This function p ⁇ will be considered valid if, when applied to the samples from which it has been deduced, it is able to classify them correctly and, in addition, when applied to the subgroup of samples that they had not been taken into account to deduce the function but whose category is known to have been previously assigned by a different method from that of the invention, it is also able to classify them correctly.
- the classifier can be obtained with the corresponding functions of the "pamr a " package of R, which also starts from the assignment of the value of probability 0 to a subgroup of members of one of the categories and the probability value 1 to a subgroup of members of the other category.
- the calculation of coefficients for statistically significant oligonucleotides allows the calculation of probability values of belonging to one or another category, also considering that the values greater than 0.5 indicate membership in the category whose members were arbitrarily assigned the value 1 and values less than 0.5 indicate membership in the other category.
- a particular case of the method of the invention is one in which it is desired to classify samples as associated or not associated with some type of leukemia.
- blood samples especially peripheral blood samples, are preferred as biological samples to carry out the method of the invention in vitro.
- the method of the invention can be used to classify samples according to the level of expression of said genes in said samples.
- the neoplasm can be, for example, a specific type of leukemia.
- a particular case of this embodiment of the method of the invention is the association of a sample with chronic lymphatic leukemia, thus allowing the diagnosis of this disease by the method of the invention.
- they are considered as significant genes whose level of expression is analyzed by applying the method of the invention at least those of the group of CD79A, FAIM3, HLA-DRA, HLA-DRB3, HLA-DQAl and the analysis is performed on samples of blood.
- the method can be applied further including analysis of the expression level of at least the IRF 8 and COL3A1 genes.
- the analysis of the expression level of these genes is performed by evaluating the level of their corresponding mRNAs by hybridization of their corresponding cRNA with oligonucleotides SGl 17, SG428, SG459, SG507, SG508, SG461 and SG493, which are preferred to be associated to a solid support forming part of a microarray.
- significant genes can be considered whose expression level is analyzed by applying the method of the invention for the diagnosis of CLL at least those of the group of CD79A, FAIM3, HLA-DRA, HLA-DRB3, HLA-DQAl, additionally including the expression level analysis of at least the CDW52 gene.
- the analysis of the expression level of these genes is performed by evaluating the level of their corresponding mRNAs by hybridization of their corresponding cRNA with oligonucleotides SGl 17, SG428, SG459, SG507, SG508 and SG237, which are preferred to be associated with a solid support forming part of a microarray.
- Another particular case of the application of the method of the invention to classify samples as associated with a specific type of leukemia according to the level of expression in said statistically significant gene samples is the classification of a sample as associated with a specific subtype of lymphatic leukemia. chronic, the "stable” LLC or the “progressive” LLC, which allows the method of the invention to predict the future evolution of subjects who have been diagnosed with LLC.
- the genes considered statistically significant to perform the classification of the samples are at least the PSMB4, FCER2 and POU2F2 genes, and the level of expression of at least one gene selected from the group composed of ODCl can be further analyzed.
- CD79A CD2, CD3E, CD5, MS4A1, EIF4E, FHIT, NR3C1, LCPl, MAPK10, ABCC5, XRCC3, CML66, PLZF, RBP4 or all of them.
- a further aspect of the invention is the use of devices to evaluate the level of expression of at least one of the genes of the group consisting of PSMB4, FCER2, POU2F2, ODCl, CD79A, CD2, CD3E, CD5, MS4A1, EIF4E, FHIT , NR3C1, LCPl, MAPKlO, ABCC5, XRCC3, CML66, PLZF, RBP4, CD79A, FAIM3, HLA-DRA, HLA-DRB3, HLA-DQAl, IRF8 and COL3A1 in order to diagnose the presence of LLC in an individual and / or forecast its evolution.
- a particular case of this aspect of the invention is the use of expression level evaluation devices of at least one gene in the group consisting of CD79A, FAIM3, HLA-DRA, HLA-DRB3, HLA-DQAl, IRF8 and COL3A1 for diagnosis of the presence of LLC in an individual, in which it is preferred that the device evaluate at least the level of expression of the CD79A, FAIM3, HLA-DRA, HLA-DRB3, HLA-DQAl genes, and the device can be evaluated, additionally , the level of expression of at least the IRF8 and COL3A1 genes or of at least the CDW52 gene.
- Another particular case of this aspect of the invention is the use of expression level evaluation devices of at least one gene of the group consisting of PSMB4, FCER2, POU2F2, ODCl, CD79A, CD2, CD3E, CD5, MS4A1, EIF4E, FHIT , NR3C1, LCPl, MAPKlO, ABCC5, XRCC3, CML66, PLZF, RBP4, CD79A, FAIM3, HLA-DRA, HLA-DRB3, HLA-DQAl, IRF8 and COL3A1 to predict the future evolution of the LLC in an individual.
- expression level evaluation devices of at least one gene of the group consisting of PSMB4, FCER2, POU2F2, ODCl, CD79A, CD2, CD3E, CD5, MS4A1, EIF4E, FHIT , NR3C1, LCPl, MAPKlO, ABCC5, XRCC3, CML66, PLZF, RBP4, CD79A, FAIM3, HLA-DRA
- genes were selected for their special involvement in the biology of blood cells or in the pathology of the different neoplasms.
- the selected genes can be included within these 4 large groups:
- the characteristics of the genes can be found, for example, at: www.ncbi.nlm.nih. gov / Genbank /, selecting the option "Gene” in the drop-down that appears and entering the corresponding identification number (GenID) in the GenBank.
- GenID identification number
- the genes whose expression can be analyzed with the microarray, their corresponding identification number in the GenBank, as well as the oligonucleotides present in the microarray to be used as probes to analyze the expression of said genes appear later in Table 1.
- GenBank For each of the 534 genes related to hematological malignancies, as well as for the genes corresponding to ⁇ -actin, glyceraldehyde-3-phosphate dehydrogenase, 18S rRNA and 28S rRNA, GenBank was searched (www.ncbi.hlm.nih. gov / Genbank /) the mRNA sequence. From the GenBank sequence, a specific oligonucleotide (probe) was designed for each of the selected genes. In some genes, several oligonucleotides located in the 5 'and 3' zones of the gene were designed to analyze the integrity of the mRNAs.
- Probes located less than 3000 nucleotides from the 3 'end (poly (A)) of the selected mRNA sequence were selected.
- Sense of the probe Thread with sense "sense” was chosen, that is to say, the sequences of the oligonucleotides coincide with sequences of fragments of the corresponding mRNAs, instead of being sequences complementary to said fragments. This decision implies that the marked genetic material has to be antisense, "antisense” (complementary to “sense”).
- probes were selected that had a homology percentage, calculated using the BLAST tool (available on the website http://www.ncbi.nlm.nih.gov/), less than 70%.
- probes were 2 pairs of oligonucleotides complementary to the 5 'and 3' ends of the ⁇ -actin genes (probes code SG463 and SG464) and glyceraldehyde-3-phosphate dehydrogenase (probes code SG466 and SG467).
- the relationship between the intensities of the probe located at the 3 'and 5' end allows checking the quality of the starting RNA and the functioning of the tidal reaction. Details on these oligonucleotides appear in Table 3.
- probes are formed mostly by a group of 50 nucleotide (50-mer) oligonucleotides that are not complementary to any known human sequence.
- 50-mer 50 nucleotide
- BLAST tool was applied to these probes and it was seen that they did not hybridize with any human sequence.
- SCl SEQ ID NO: 564
- SC2 SEQ ID NO: 565
- SC3 SEQ ID NO: 566
- SC4 SEQ ID NO: 567
- SC5 SEQ ID NO: 568
- SC6 SEQ ID NO: 569
- SC7 SEQ ID NO: 570
- SCN1 SEQ ID NO: 571
- SCN5 SEQ ID NO: 575
- SCN7 SEQ ID NO:
- “Spiked controls” are synthetic oligonucleotides whose sequence coincides with a fragment of a transcript of a non-human gene or any other nucleotide sequence of low homology with human gene transcripts that are 3 'polyadenylated, which are used as a positive control , in determining the quality of the process, in the normalization of data and for the establishment of the linear range of the process (Benes V et al., 2003). To this end, the corresponding polyadenylated transcripts or sequences are added to the total starting RNA before starting the screening process and, therefore, undergo the same reactions (marking, hybridization and development) as the total RNA of the samples.
- Plasmids contained the cloned cDNA of a gene from Bacillus subtilis, with cut sites for the enzymes Notl at the 5 'end and BamHI at the 3' end and a poly (dA) extension anterior to the cut site for BamHI.
- the plasmid was obtained with the Midipreps kit (Jetstar) following the manufacturer's recommendations. 10 ⁇ g of each of the plasmids was linearized by digestion with 30U of Notl restriction enzyme, in the presence of 1XNE3 and IXBSA buffer for 3 hours at 37 ° C. The linearized plasmids were subjected to phenol extraction: chloroform: isoamyl alcohol (Ambion), precipitation with 0.1 vol of 3M sodium acetate (Sigma) and 2.5 vol of 100% Ethanol and removal of salts with 80% Ethanol, following the protocol described above.
- the DNA obtained was resuspended in 10 ⁇ l of RNase free water. Subsequently, the sense transcripts were synthesized with an in vitro Transcription reaction (IVT) from 1 ⁇ g of linearized plasmid using the MegaScript T3 kit (Ambion) and following the manufacturer's recommendations.
- IVTT in vitro Transcription reaction
- the plasmids obtained were purified with the RNeasy Total RNA Isolation Kit (QIAGEN), following the manufacturer's recommendations.
- the recombinant plasmids contained the cloned cDNA of the two sppvl and sspv2 genes inserted between two restriction sites PvuII and PstI.
- the 3 'end of each insert contains a polyadenylation extension.
- JMl 09 cells were transformed with the plasmids containing the transcripts. The cells were grown on plates with LB + Ampicillin medium at 37 ° C, colonies with the transformed cells were selected and grown in LB + AMP liquid medium.
- Plasmid recovery was performed with the Midipreps Plasmid Purification kit (Qiagen), following the manufacturer's recommendations. 10 ⁇ g of each plasmid was linearized with 30U of the PvuII restriction enzyme. The insert was extracted with phenol: chloroform: isoamyl alcohol (Ambion), precipitation with 0.1 volumes of 7.5 M sodium acetate and 2.5 volumes of 100% ethanol. The salts were removed by two washes with 80% ethanol. The DNA obtained was resuspended in 10 ⁇ l of RNase free water.
- the transcripts were then synthesized from 1 ⁇ g of each plasmid linearized with the T7 MegaScript kit (Ambion) and following the manufacturer's recommendations.
- the reaction product was cleaned with the RNeasy Total RNA Isolation Kit (Qiagen).
- 70 nucleotide (70-mer) synthetic DNA oligonucleotides modified at one end with a biotin molecule were used. These molecules are added in the same amount to the sample just before hybridization, so that their value depends solely on the processes of hybridization, development and image capture of the "microarray”. For each of these 70-mer oligonucleotides, there are several copies of an oligonucleotide 50 nucleotides in length (50-mer), complementary to the corresponding 70-mer oligonucleotide with which it should hybridize.
- the 50-mer oligonucleotides that are part of the microarray and that are Complementary to 70-mer oligonucleotides that are added to the cRNA before hybridizing are those of the codes SCN2, SCN3, SCN6, SCN8, SCNI l, SCN12 and SCNl 3.
- the hybridization control solution containing the 70-mer oligonucleotides complementary to the 50-mer oligonucleotides present in the microarray as positive hybridization controls prepared from of the corresponding 70-mere biotinylated sequences using a different concentration for each of them, as shown in Table 6:
- DMSO Dimethyl sulfoxide
- the quality control of the production process of the "microarrays” was as follows: a) A "microarray” with Ethidium Bromide was stained in each production batch, which allows the size and shape of the printed dots to be analyzed, b) Other "array” of each batch was hybridized with an already hybridized cRNA, analyzing the hybridization signal, the background noise and the reproducibility of the replicas.
- RNAlater (Ambion Inc) and stored at -80 0 C until RNA extraction.
- RNA was extracted with TRIzol (Gibco-BRL Carlbad, CA, USA) following the manufacturer's recommendations.
- RNA samples were collected directly on PAXgene Blood RNA Tubes -PreAnalytix (Qiagen) tubes. 2.5 ml of blood was drawn in each tube and two tubes per individual. The tubes were inverted several times to allow the blood to mix with the liquid stabilizer containing tube, and stored at -20 0 C until the night before extracting RNA
- RNA extraction tubes with the sample were incubated at room temperature the night before RNA extraction.
- PAXgene Blood RNA kit (Qiagen) was used following the manufacturer's recommendations, including the intermediate step of DNase treatment (RNase-Free DNase Set, Quiagen) in the column.
- the RNA of each extraction tube was eluted in 80 ⁇ l of BR5 buffer.
- the RNA of the two tubes that corresponded to each patient was combined in a single tube.
- RNA obtained was free of contaminants that may interfere with subsequent tidal reactions. It was purified as follows: to 160 ⁇ l of total RNA solution was added 16 ⁇ l (0.1 vol) of sodium acetate 7.5 M (Sigma) and 400 ⁇ l (2.5 vol) of 100% ethanol. The solution was mixed in a "vortex" stirrer and incubated for 1 hour at -20 0 C. After 20 minutes of centrifugation at 12,000xg at 4 ° C, the precipitate was washed twice with 500 ⁇ l of ethanol 80% and resuspended in 35 ⁇ l of RNase free water. The RNAs obtained were stored at -80 0 C until later use.
- the quantification of the total RNA was carried out by measuring the absorbance at 260 nm in a spectrophotometer (DU 65, Beckman Coulter). 2 ⁇ l of the total RNA solution was diluted in 98 ⁇ l of 1 mM Tris-HCl pH 7.5 and the concentration ( ⁇ g / ml) was estimated taking into account that 1 Unit of Optical Density at 260 nm corresponds to a concentration of 44 ⁇ g / ml RNA.
- the degree of purity was established from the ratio of absorbances A260 / A280 (nucleic acid / proteins), considering that the RNA is adequate, of "good quality", when the ratio A260 / A280 is between 1.9 and 2 ,one.
- RNA quality was determined by visualization of RNA after electrophoresis.
- 500 ng of total RNA were subjected to 1% agarose gel electrophoresis (FMC) in TAE Ix buffer with BrEt (0.5 mg / ml), under a potential difference of 100V for 25 minutes in current electrophoresis cuvettes continuous (BioRad).
- the ⁇ 29 phage digested with the restriction enzyme BamH I was used as a molecular weight marker.
- the gels were visualized in a GeI Doc ultraviolet light transilluminator (BioRad).
- This type of marking was carried out during the course of an amplification process that consists of the use for the synthesis of single stranded cDNA, of an oligo (dT) primer that contains a promoter for the enzyme RNA polymerase of phage TJ, an enzyme that will be used in the stage of amplification of the sample.
- a.- Synthesis of cDNA stage in which complementary DNA (cDNA) was synthesized to the starting mRNA.
- RNAtotal 5 .mu.g of RNAtotal was incubated with 2 ul of the solution of "Spiked controls" and 100 pmol T7 primer (dT) 24 (Genset Corp) in a final volume of 12 .mu.l for 10 minutes at 70 0 C in a thermoblock, the mixture was cooled on ice and 4 ⁇ l of 5X First Strand Buffer buffer (Gibco BRL Life Technologies), 2 ⁇ l DTT 0.1M (Gibco BRL Life Technologies), 1 ⁇ l dNTP mix 1OmM (Gibco BRL Life Technologies) were added and 1 ⁇ l of SuperScript II RNase H RT (200 U / ⁇ l) (Gibco BRL Life Technologies). After 1 hour incubation in a thermostat bath (Selecta) at 42 ° C, the reaction was cooled on ice.
- 5X First Strand Buffer buffer Gibco BRL Life Technologies
- DTT 0.1M Gibco BRL Life Technologies
- dsDNA double stranded DNA
- reaction was incubated in a thermoblock at 16 ° C for 2 hours. Then 10U of T4 DNA Polymerase (Gibco BRL Life Technologies) was added and the mixture was incubated for 5 minutes at 16 ° C. To stop the reaction, 10 ⁇ l of 0.5 M ⁇ DTA was added.
- c- Purification of the dsDNA To eliminate possible remains of reaction products that may interfere with subsequent tidal reactions, the DNA obtained was purified through phenol / chloroform extraction and subsequent precipitation. To the 162 ⁇ l of the above reaction was added 162 ⁇ l of the phenol: chloroform: isoamyl alcohol solution (25: 24: 1) (Ambion). It was centrifuged for 2 min at 12,000xg in a centrifuge at room temperature, the upper aqueous phase was collected. To this upper layer was added 0.5 volumes of 7.5M ammonium acetate (Sigma Chemical) and 2.5 volumes of 100% ⁇ tanol cooled to -20 0 C).
- biotinylated cRNA was purified with the RNeasy Total RNA Isolation Kit (Qiagen) according to the manufacturer's instructions. Biotinylated cRNAs obtained were eluted in a volume of 80 .mu.l and stored at -80 0 C until use.
- the quantity, purity and quality of the cRNA obtained were determined following the same procedures as described for total RNA.
- the cRNA was stored at -80 0 C until later use.
- the labeled genetic material was contacted with the probes immobilized on the solid support.
- 10 ⁇ l of the hybridization control solution was added and the mixture was incubated 3 min at 95 ° C to denature the possible secondary structures. After incubation, the mixture was immediately taken to ice to prevent possible renaturation of the sample.
- Hybridization was carried out for 6 hours at 42 ° C in the automatic hybridization station Ventana Disco very (Ventana Medical Systems). Hybridization and wash buffers were supplied by Ventana Medical System. The "microarrays" were automatically stained in the hybridization station with streptavidin conjugated with Cy3 (Amersham Biosciences) using the manufacturer's recommendations.
- the images of the "microarrays” were identified and analyzed by means of the ScanArray 4000 confocal fluorescent "scanner” (Perkin Elmer) equipped with a green laser (543 nm to excite Cy3 fluorophore).
- the "software” used was ScanArray 3.1.
- the use of the QuantArray 3.0 software provided the absolute values of the hybridization intensity and background noise as a function of the light emitted by Cy3 in each probe in an Excel format.
- the absolute intensity values of all oligonucleotides were subtracted from the background noise value.
- the absolute intensity values and background noise values were used that the program used to convert the fluorophore signals automatically returns for each of the microarray points: the corresponding intensity value is obtained from the zone that has been defined as a point and the background noise value is obtained from the area around the point.
- the average hybridization intensity level of each of the oligonucleotides of the microarray was then calculated from the bounded average of the intensities of the 12 replicates of each of the oligonucleotides. To do this, they have of eliminating, before calculating the mean, the superior values and the inferior values of the distribution of points of hybridization signal values obtained with each of the replicas of the same oligonucleotide.
- the calculation was made using the Microsoft Excel program and, specifically, the MEDIA.ACOTADA function of it, in which the parameter "percentage" was set at 0.2, which means setting the percentage of values eliminated at 20% of the higher values and 20% of the lower values; the function rounds the number of data points excluded to the nearest multiple of 2.
- the ratio between the average intensity and the average background of all the oligonucleotides of the chip is greater than 10; 2) the value of the mean variation coefficient (standard deviation of the replicas versus the average of the replicas) of all oligonucleotide replicas of the chip must be less than 0.3; 3) the average value of the negative control must be less than 2.5 times the value of the average DMSO; 4) signal should be obtained both in hybridization controls and in exogenous internal positive controls (Spiked controls).
- R Data analysis was performed in R, version 1.9.1.
- R is a programming language in which both classical and modern statistical techniques can be applied (R Developmental Core Team, 2004; http://www.R-project.org), which has a series of functions stored in packages for the manipulation, calculation and graphic representation of data (Venables et al, 2004).
- R There are hundreds of packages written by different authors for R, with special statistical functions or that allow access and manipulation of data and are available for download from the CRAN web pages (http://cran.r-project.org/) or Bioconductor (http://www.bioconductor.org).
- the commercial statistical analysis software SPSS (Chicago, USA) was also used. Examples
- the device In order to know if the device allows two cell lines to be differentiated, they were hybridized into 10 microchips: 5 samples of biotinylated cRNAs synthesized following the optimized working protocol, obtained from RNA from U937 cells (cell line from Promonocytic Leukemia) and 5 samples of biotinylated cRNAs obtained from Jurkat cell RNA (cell line from Leukemia T).
- the unsupervised analysis of the 10 samples produced their separation into two main groups or branches depending on the cell type to which the samples belong: one group contains the 5 hybridizations performed to from U937 cells and the other group contains the 5 hybridizations made from Jurkat cells.
- the resulting tree of this unsupervised grouping is shown in part A of Figure 1.
- the "Step-down maxT multiple testing procedures" (maxT) method was used, which is an application of the mt.maxT function of the R software multtest package Bioconductor, which applies a statistical test and performs a strong control over the false positive rate.
- This function must be provided: a) Values on which the statistical test is to be applied, in this case, on the normalized values of the 83 oligonucleotides that exceeded the filters b) Groups from which we want to look for differences, in this case the 5 samples of Jurkat cells versus the 5 samples of U937 cells c) Number of permutations to be performed. In this case 100,000 permutations were performed.
- the supervised grouping of the samples was performed based on the signal strength of the 69 probes statistically significant obtained.
- the term "supervised”, applied to a grouping refers to the fact that the structure of the data is known in advance, which makes it possible to use the previous information; with this, after a training process that allows the system to learn to distinguish between classes, the network can be used to assign new members to the predefined classes.
- the supervised grouping of the samples based on the intensity of the signal obtained with the 69 statistically significant probes obtained is again a tree that is divided into two main branches depending on the cell type to which the samples belong. The tree obtained with the supervised grouping is shown in part B of Figure 1.
- the expression of 5 samples of U937 cells and 5 samples of Jurkat cells was compared against the expression of 10 samples from whole blood of healthy subjects Similar to that described in Example 1, the initial data processing, hybridization validation, normalization and filtering steps were carried out. A total of 180 genes exceeded the filtering processes.
- the unsupervised grouping of samples (performed with the hclust function of the R stats package applying Pearson's correlation) in conjunction with the expression of the 180 genes provided a tree with two main branches: one branch contains all samples from cell cultures and the other branch contains all samples from whole blood of healthy subjects, so it is shown that the tool is able to find differences in expression.
- the tree obtained after performing this unsupervised grouping is shown in part A of Figure 2.
- the maxT test (p ⁇ 0.001) was performed to search for genes with statistically significant differences between samples from U937 and Jurkart cell cultures and the 10 samples from whole blood from healthy subjects. Statistical analysis provided a list of 131 probes with statistically significant differences between both groups of samples.
- the samples were subjected to preliminary data processing, normalized and filtered analogously to that used in Examples 1 and 2 and a total of 236 probes exceeded the filters.
- the unsupervised grouping of the samples based on the expression of the probes that exceeded the filters showed a tree with two main branches: one containing the cell culture samples and the other the LLC samples. Said tree is shown in part A of Figure 3.
- SG2 SG4, SG8, SGlO, SG13, SG15, SG16, SG19, SG20, SG23, SG26, SG28, SG31, SG34, SG36, SG39, SG48, SG58, SG60, SG65, SG76, SG77, SG84, SG89, SG94, SG9, SG97, SG99, SG102, SG106, SG107, SG463, SG464, SG474, SG475, SG481, SG465, SG485, SG487, SG466, SG467, SG471, SG473, SGl 15, SGl 16, SGl 17, SG120, SG129, SG134 , SG135, SG138, SG139, SG141, SG145, SG158, SG161, SG163, SG176, SG178, SG185, SG207, SG208, SG210,
- the grouping of the 30 samples based on the expression of the 120 statistically significant probes gave rise again to a tree with two main branches, one corresponding to the cell culture samples and the other corresponding to the samples taken from subjects suffering from CLL. .
- This tree is shown in part B of Figure 3.
- 68 hybridizations that met the quality criteria from 68 samples of different healthy subjects and with clinical diagnosis of CLL were divided into 2 groups: Training Group used to obtain the functions of the classifier and Test Group, used to test the classifier obtained.
- the Training Group was composed of 30 samples (10 of healthy subjects and 20 of LLC subjects) and the Test Group was composed of 38 samples (5 samples of healthy subjects and 33 samples of subjects with LLC).
- PAM Prediction Analysis for Microarrays
- PAM classifier validation Cross-validation of the samples that make up the Training Group correctly classified 28 of the 30 samples.
- Xi Constant + (Coef ohle0009 * Imni SGl 17) + (Coef SG428 * Imni SG428) + (Coef SG459 * Irruii SG459) + (Coef SG461 * Iimii SG461) + (Coef SG493 * Iirnii SG493) + (Coef SG507 * Iimii SG507 * Iimii SG507 * Iimii SG507 * Iimii SG507 * ) + (Coef SG508 * Iirun SG508).
- Imnj is the average normalized intensity value of the sample i.
- a probability value (pi) is calculated from the value x ⁇ .
- the formula used to determine the value of p is:
- a third group of 40 samples was formed. For this, hybridization or mareaje replicas were used (samples whose designation begins with S and Strans are samples of people considered healthy and those that begin with CLL samples from patients with chronic lymphatic leukemia). This group of samples was used for the validation of the classification system. The data was normalized as described above. The results of the classification are shown in Table 13. 40 of the 40 samples are correctly classified.
- Samples of patients who are more than 5 years with stable LLC and samples of "LLC-progressive type" (P) "progressive type” are considered to be samples of patients classified as stable in the moment of diagnosis and whose disease has progressed in less than a year.
- oligonucleotides obtained were: SG26, SG31, SG70, SG98, SG177, SG194, SG195, SG208, SG213, SG216, SG272, SG293, SG301, SG309, SG321, SG333, SG343, SG352, SG357, SG366, SG368, SG405 , SG426, SG439, SG447, SG452, SG521, SG555, SG556.
- the technique used for validation was real-time RT-PCR or PCR using a LightCycler. This technique is the technique of choice to validate chip data and, like microarrays, it measures mRNA level.
- Figure 5 shows the distribution of the expression data obtained by RT-PCR (graphics on the left side) and by microarray (graphics on the right side).
- Part A corresponds to the PSMB4 gene
- part B to the CD23A gene
- part C to the POU2F2 gene.
- lymphochip a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. CoId Spring Harb Symp Quant Biol. 1999; 64: 71-8.
- Cossman J Gene expression analysis of single neoplastic cells and the pathogenesis of Hodgkin's lymphoma. J Histochem Cytochem 2001; 49: 799-800 Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348: 1764-75
- Dohner K Tobis K, Ulrich R, Frohling S, Benner A, Schlenk RF, Dohner H. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years oid with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group UIm. J Clin Oncol. 2002; 20: 3254-61
- Domen J, Weissman IL Self-renewal, differentiation or death: regulation and manipulation of hematopoietic stem cell fate. Mol Med Today. 1999; 5: 201-8
- KyIe RA Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: Implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am 11: 71, 1997
- Mitelman F Mertens F, Johansson BA breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 1997; 15 Spec No: 417-74 Montoto S, Lopez-Guillermo A, Colomer D, et al. Incidence and clinical significance of bcl-2 / IgH rearrangements in follicular lymphoma. Leuk Lymphoma. 2003; 44: 71-6.
- Weissman IL Stem cells Units of regeneration and units in evolution. CeIl, 2000; 100: 157-168.
- Figure 1 shows the grouping of U937 cell samples against Jurkat cells as a function of differences in gene expression between the samples.
- Part A corresponds to the unsupervised grouping
- Part B corresponds to the supervised grouping.
- Figure 2 shows the grouping of samples of healthy subjects against U937 cells and Jurkat cells as a function of differences in gene expression between the samples.
- Part A corresponds to the unsupervised grouping
- Part B corresponds to the supervised grouping.
- Figure 3 shows the grouping of samples from patients with chronic lymphatic leukemia against U937 cells and Jurkat cells based on differences in gene expression between the samples.
- Part A corresponds to the unsupervised grouping
- Part B corresponds to the supervised grouping.
- Figure 4 shows the grouping of samples from patients with "stable" chronic lymphatic leukemia versus samples from patients with "progressive" chronic lymphatic leukemia based on differences in gene expression.
- Part A corresponds to the grouping according to the genes identified as significant after normalization with "vsn” and use of the mt.maxT function of R;
- part B corresponds to the grouping according to the genes identified as significant after normalization by robust quantiles and use of the mt.maxT function of R.
- Figure 5 shows the distribution of the expression data obtained by RT-PCR (graphs on the left side) and from the intensity values obtained from the microarray (graphs on the right side) for the PSMB4 genes (part A: upper graphs) ), CD23A (part B: intermediate graphics) and POU2F2 (part C: lower graphics) in samples of patients with "stable” chronic lymphatic leukemia (bars marked “E”) and in samples of patients with "progressive" chronic lymphatic leukemia (bars marked “P”).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006307849A AU2006307849B2 (en) | 2005-10-27 | 2006-05-08 | Method and device for the in vitro analysis of mRNA of genes involved in haematological neoplasias |
BRPI0617889-8A BRPI0617889A2 (pt) | 2005-10-27 | 2006-05-08 | procedimento e dispositivo de análise in vitro de mrna de genes envolvidos em neoplasias hematológicas |
EP06743492A EP1947194A4 (en) | 2005-10-27 | 2006-05-08 | METHOD AND DEVICE FOR IN VITRO ANALYSIS OF MRNA OF GENES INVOLVED IN HEMATOLOGIC NEOPLASIA |
CA002626513A CA2626513A1 (en) | 2005-10-27 | 2006-05-08 | Method and device for the in vitro analysis of mrna of genes involved in haematological neoplasias |
US12/083,824 US20120157329A1 (en) | 2005-10-27 | 2006-05-08 | Method and Device for the in Vitro Analysis for MRNA of Genes Involved in Haematological Neoplasias |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200502618 | 2005-10-27 | ||
ES200502618A ES2324435B1 (es) | 2005-10-27 | 2005-10-27 | Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007048866A1 true WO2007048866A1 (es) | 2007-05-03 |
Family
ID=37967431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2006/070054 WO2007048866A1 (es) | 2005-10-27 | 2006-05-08 | PROCEDIMIENTO Y DISPOSITIVO DE ANÁLISIS IN VITRO DE mRNA DE GENES IMPLICADOS EN NEOPLASIAS HEMATOLÓGICAS |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120157329A1 (es) |
EP (1) | EP1947194A4 (es) |
AU (1) | AU2006307849B2 (es) |
BR (1) | BRPI0617889A2 (es) |
CA (1) | CA2626513A1 (es) |
ES (1) | ES2324435B1 (es) |
RU (1) | RU2426786C2 (es) |
WO (1) | WO2007048866A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9846762B2 (en) | 2007-03-22 | 2017-12-19 | University Of South Florida | Gene signature for the prediction of radiation therapy response |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008014608A (es) | 2006-05-18 | 2009-03-31 | Molecular Profiling Inst Inc | Sistema y metodo para determinar la intervencion medica individualizada para un estado de enfermedad. |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
WO2009106372A1 (en) * | 2008-02-29 | 2009-09-03 | Istituto Superiore Di Sanatà | Diagnostic method |
CA2734123A1 (en) * | 2008-08-15 | 2010-02-18 | Decode Genetics Ehf | Genetic variants predictive of cancer risk |
US7897356B2 (en) | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
CA2791905A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarkers for theranostics |
US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
EP2385134A1 (en) * | 2010-05-07 | 2011-11-09 | Ludwig-Maximilians-Universität München | Risk prognosis method for chronic lymphocytic leukemia |
ES2614978T3 (es) | 2010-12-22 | 2017-06-02 | Universite Francois Rabelais De Tours | Procedimiento de diagnóstico de trastornos hematológicos |
CA3177515A1 (en) * | 2012-03-12 | 2013-09-19 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
JP2016513974A (ja) * | 2013-03-14 | 2016-05-19 | チルドレンズ メディカル センター コーポレーション | 造血幹細胞系列を初期化するための組成物および方法 |
WO2015178804A1 (ru) * | 2014-05-19 | 2015-11-26 | Общество С Ограниченной Ответственностью "Гамма Глобал Рд" | Способ определения вероятности рецидивирования рака молочной железы |
CN107636162B (zh) | 2015-06-01 | 2021-12-10 | 加利福尼亚技术学院 | 用针对特定群体的抗原筛选t细胞的组合物和方法 |
US11008623B2 (en) | 2016-02-17 | 2021-05-18 | The Penn State Research Foundation | Comparing PIGN transcription and translation levels and sequencing to locate a PIGN mutation |
RU2614117C1 (ru) * | 2016-03-09 | 2017-03-22 | Федеральное государственное бюджетное научное "Всероссийский научно-исследовательский институт животноводства имени академика Л.К. Эрнста" (ВИЖ им. Л.К. Эрнста) | Способ определения полиморфизма apaf1, ассоциированного с гаплотипом фертильности голштинского скота hh1 |
AU2018423766A1 (en) * | 2018-05-17 | 2020-12-24 | Twobull Meditherapy P.C. | Diagnostic blood test |
CN110221335B (zh) * | 2019-06-21 | 2022-07-01 | 南华大学 | 一种利用转铁蛋白受体1评价低剂量伽马射线辐射损伤的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008552A2 (en) | 2001-07-17 | 2003-01-30 | Whitehead Institute For Biomedical Research | Mll translocations specify a distinct gene expression profile, distinguishing a unique leukemia |
WO2003062401A2 (en) * | 2002-01-22 | 2003-07-31 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
WO2005024043A2 (en) | 2003-09-03 | 2005-03-17 | Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
WO2005080601A2 (en) * | 2004-02-23 | 2005-09-01 | Erasmus Universiteit Rotterdam | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0207657A (pt) * | 2001-02-28 | 2004-10-26 | Chondrogene Inc | Uma ou mais sequências de polinucleotìdeos isoladas, vetor, célula hospedeira, composição, disposição, métodos para diagnosticar as osteoartrites branda, moderada, acentuada e grave em um paciente, para identificar um agente que aumenta ou diminui a expressão de uma sequência de polinucleotìdeos, para preparar uma coleção de cdna de condrócito, e para fabricar uma disposição, e conjunto |
EP1308522A1 (en) * | 2001-11-05 | 2003-05-07 | Haferlach, Torsten, PD Dr. Dr. | Novel genetic markers for leukemias |
US20040018513A1 (en) * | 2002-03-22 | 2004-01-29 | Downing James R | Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling |
WO2005020784A2 (en) * | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
-
2005
- 2005-10-27 ES ES200502618A patent/ES2324435B1/es not_active Expired - Fee Related
-
2006
- 2006-05-08 WO PCT/ES2006/070054 patent/WO2007048866A1/es active Application Filing
- 2006-05-08 CA CA002626513A patent/CA2626513A1/en not_active Abandoned
- 2006-05-08 US US12/083,824 patent/US20120157329A1/en not_active Abandoned
- 2006-05-08 AU AU2006307849A patent/AU2006307849B2/en not_active Ceased
- 2006-05-08 EP EP06743492A patent/EP1947194A4/en not_active Withdrawn
- 2006-05-08 BR BRPI0617889-8A patent/BRPI0617889A2/pt not_active IP Right Cessation
- 2006-05-08 RU RU2008120600/10A patent/RU2426786C2/ru not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008552A2 (en) | 2001-07-17 | 2003-01-30 | Whitehead Institute For Biomedical Research | Mll translocations specify a distinct gene expression profile, distinguishing a unique leukemia |
WO2003062401A2 (en) * | 2002-01-22 | 2003-07-31 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
WO2005024043A2 (en) | 2003-09-03 | 2005-03-17 | Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
WO2005080601A2 (en) * | 2004-02-23 | 2005-09-01 | Erasmus Universiteit Rotterdam | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
Non-Patent Citations (66)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9846762B2 (en) | 2007-03-22 | 2017-12-19 | University Of South Florida | Gene signature for the prediction of radiation therapy response |
Also Published As
Publication number | Publication date |
---|---|
AU2006307849B2 (en) | 2012-07-05 |
CA2626513A1 (en) | 2007-05-03 |
ES2324435A1 (es) | 2009-08-06 |
EP1947194A1 (en) | 2008-07-23 |
EP1947194A4 (en) | 2010-01-20 |
AU2006307849A1 (en) | 2007-05-03 |
BRPI0617889A2 (pt) | 2011-08-09 |
ES2324435B1 (es) | 2010-05-31 |
RU2426786C2 (ru) | 2011-08-20 |
RU2008120600A (ru) | 2009-12-10 |
US20120157329A1 (en) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007048866A1 (es) | PROCEDIMIENTO Y DISPOSITIVO DE ANÁLISIS IN VITRO DE mRNA DE GENES IMPLICADOS EN NEOPLASIAS HEMATOLÓGICAS | |
US20230193396A1 (en) | Circulating microrna signatures for ovarian cancer | |
US20180011106A1 (en) | Methods for identifying, diagnosing, and predicting survival of lymphomas | |
US20090253583A1 (en) | Hematological Cancer Profiling System | |
CN110317875A (zh) | 一种与肺癌相关的甲基化基因及其检测试剂盒 | |
Dunphy | Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications | |
WO2013074044A1 (en) | Methods for diagnosis and/or prognosis of gynecological cancer | |
US20140100125A1 (en) | Methods, Kits and Compositions for Determining Severity and Survival of Heart Failure in a Subject | |
Bahloul et al. | Clinical impact of molecular diagnostics in low-grade lymphoma | |
US8530155B2 (en) | Methods for diagnosis of common acute lymphoblastic leukemia by determining the level of gene expression | |
CA2475769C (en) | Colorectal cancer prognostics | |
US20050048494A1 (en) | Colorectal cancer prognostics | |
KR100835296B1 (ko) | 암 예측 유전자세트 선정방법 | |
BR112020012280A2 (pt) | composições e métodos para diagnosticar cânceres de pulmão usando perfis de expressão de gene | |
Dickinson et al. | Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect | |
MX2008004462A (es) | Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas | |
Do et al. | Comparison of genomic profiles in human neuroblastic SH-SY5Y and substrate-adherent SH-EP cells using array comparative genomic hybridization | |
Al Seraihi et al. | Genomics and Diagnostics in Acute Myeloid Leukaemia | |
JPWO2015105191A1 (ja) | リンパ節腫脹病変の評価方法 | |
Roode | Molecular Characterization of Canine Leukemia--Comparative Value and Clinical Applications. | |
HEMATOLOGIC | Important Chromosomal Aberrations in Hematologic Neoplasms and Key Techniques to Diagnose Them | |
EP1530046A9 (en) | Method for distinguishing AML subtypes with aberrant and prognostically intermediate karyotypes | |
Boerma | Molecular definition of Burkitt Lymphoma | |
Canzian | Identification of polymorphic miRNA-binding sites associated with the risk of multiple myeloma | |
Klein | Gene Expression Profiling in the Study of Chronic Lymphocytic Leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/004462 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2626513 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006743492 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006307849 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006307849 Country of ref document: AU Date of ref document: 20060508 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006307849 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008120600 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006743492 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12083824 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0617889 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080425 |